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Abstract 1 
 2 
Neurotrophic Keratopathy (NK) refers to a condition where corneal epitheliopathy leading to 3 
frank epithelial defect with or without stromal ulceration (melting) is associated with reduced or 4 
absent corneal sensations. Sensory nerves serve nociceptor and trophic functions, which can be 5 
affected independently or simultaneously. Loss of trophic function and consequent epithelial 6 
breakdown exposes the stroma making it susceptible to enzymatic degradation. Nerve pathology 7 
can range from attrition to aberrant re-generation with corresponding symptoms from anaesthesia 8 
to hyperaesthesia/allodynia.  Many systemic and ocular conditions, including surgery and 9 
preserved medications can lead to NK. NK can be mild (epithelium and tear film changes), 10 
moderate (non-healing epithelial defect) or severe (stromal melting and perforation). Moderate 11 
and severe NK can profoundly affect vision and adversely impact on the quality of life. Medical 12 
management with lubricating agents from artificial tears to serum/plasma drops, anti-13 
inflammatory agents, antibiotics and anti-proteases all provide non-specific relief, which may be 14 
temporary. Contact lenses, punctal plugs, lid closure with botulinum toxin and surgical 15 
interventions like tarsorrhaphy, conjunctival flaps and amniotic membrane provide greater 16 
success but often at the cost of obscuring sight. Corneal surgery in a dry ocular surface with 17 
reduced sensation is at high risk of failure. The recent advent of biologicals such as biopolymers 18 
mimicking heparan sulfate; coenzyme Q10 and antisense oligonucleotide that suppress connexin 19 
43 expression, all offer promise. Recombinant nerve growth factor (cenegermin), recently 20 
approved for human use targets the nerve pathology and has the potential of addressing the 21 
underlying deficit and becoming a specific therapy for NK. 22 
 23 
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1. Introduction 31 
 32 
The ocular surface is a continuous epithelium and underlying stroma extending from the 33 
muco-cutaneous junction at the eye lid margin to the corneal surface. It is a specialised system 34 
that closely interacts with associated adnexal structures, lacrimal glands and eyelids (known as 35 
the lacrimal functional unit), and via cross-talk with the neural, endocrine, vascular, and immune 36 
regulatory systems (Gipson, 2007). Aragona and Rolando described the ocular surface unit as a 37 
dynamic complex that includes the eye lids, tear film, conjunctiva and cornea functioning as a 38 
single unit, where one reflects and influences the others (Aragona and Rolando, 2013). It 39 
represents the interface between the external environment and the eye. Its key function is to 40 
guarantee a clear optical surface to direct light to the retina, a neural tissue inside the eye that 41 
signals to the brain for visual recognition. It also provides protection for the inner structures of 42 
the eye. To do this it must be able to quickly adapt to the changing conditions of the environment 43 
or pathologic stresses, and generate functional and anatomical responses to maintain 44 
homeostasis. An integration among neural, cellular, immune, and tear film related responses is 45 
the basis of its ability to react and adapt quickly. Proper function of the tear film, lids and 46 
conjunctiva and their neural, hormonal, immune connections are all essential in maintenance of 47 
the cornea (Rolando and Zierhut, 2001). The inability to adapt or failure of one or more of its 48 
components gives rise to vicious cycles of inflammation and damage, which if not promptly 49 
contained will initiate and maintain ocular surface disease. Ocular surface disease is therefore the 50 
result of a progressive cascade of events involving simultaneously or sequentially, one or more 51 
of the different components of the system that is unable to compensate, respond and heal 52 
(Aragona and Rolando, 2013; Baudouin et al., 2013). 53 
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The avascular, squamous corneal epithelium is innervated by a dense mesh of sensory 54 
processes derived from the ophthalmic branch of the trigeminal nerve (Muller et al., 2003). 55 
These nerve endings are responsible for nociception, cold and pressure sensation. The 7000 56 
nerve receptors per square mm of the cornea and their fibres are involved in protecting the 57 
cornea from damage by modulating the blink response, stimulating the production of tears and 58 
maintaining the cornea in a healthy state through the production of trophic factors (You et al., 59 
2000). Nerve malfunction is the hallmark of neurotrophic keratopathy (NK).  Corneal epithelial 60 
cells constantly turnover by cell desquamation at the surface, cell regeneration at the limbus and 61 
centripetal sliding and migration from the limbus. When the epithelium is injured, cells 62 
surrounding the wound migrate onto the wound bed to re-establish cover. This repair requires a 63 
controlled and collaborative system of communication between epithelial and neuronal cells to 64 
facilitate re-synthesis of the damaged matrix, cell migration and restoration of architecture 65 
(Zieske and Gipson, 1986). If epithelial healing is impaired, the exposed stroma becomes 66 
vulnerable to enzymatic degradation, melting and eventually perforation; features that represent 67 
severe NK (Fini et al., 1998). 68 
 69 
2. Brief History of Neurotrophic Keratopathy 70 
 71 
That transection of the trigeminal nerve can lead to degenerative changes in the cornea was 72 
first described by Magendie in 1824 (Magendie, 1824), and Middlemore in 1835 recognized that 73 
the cornea was one of the most sensitive structures in the body (Middlemore, 1835). Changes of 74 
a destructive nature were not confined to the cornea alone; similar changes were noted in the skin 75 
corresponding to the area supplied by the nerve transected or damaged. The skin changes 76 
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included a sensory deficit, vasodilation, swelling and the development of trophic ulcers also 77 
described in the past as “sluggish” ulcers (Dubler, 1884). The term ‘trophic’ relates to nutrition. 78 
A trophic nerve would be one that is associated with nutrition or regulates the metabolism of 79 
cells. It was initially considered that the Vth cranial nerve carried trophic fibres (sympathetic) 80 
but this has never been proven. Besides the trophic hypothesis, various other hypotheses were 81 
put forth to explain the corneal changes that follow trigeminal nerve damage: irritative nerve 82 
action wherein the damaged corneal nerves generate harmful stimuli;  vascular or vasomotor 83 
disturbance related to loss of control of limbal and conjunctival vessels; trauma, which is of real 84 
concern as wounds heal slowly and an eye that is protected from trauma (eye closure) suffers 85 
less; desiccation and dehydration; infection; consequential cell damage and abnormal cell 86 
metabolism. Of these, the hypothesis of altered cell metabolism is the most popular and most 87 
likely. This implies that there is a “lack of normal peripheral antidromic activity of sensory 88 
nerves” (normally an impulse travels from the site of origin in the soma along the axon towards 89 
the central neuron – orthodromic. Movement in the opposite direction is antidromic). This leads 90 
to the accumulation of metabolites which in turn cause tissue swelling, loss of vitality and 91 
desquamation with the formation of a trophic ulcer. The term used to describe this condition was 92 
neuroparalytic keratitis (Klein, 1943). 93 
 94 
3. Nomenclature  95 
 96 
Various terms are used to describe corneal nerve related pathology. These are listed in table 97 
1. The nomenclature is based on the major clinical presentation of an epithelial defect (non-98 
healing, slow-healing or persistent) and the underlying nerve pathology, which has a common 99 
acronym of ‘NK’ for neuroparalytic, neuropathic or neurotrophic keratitis/keratopathy. The 100 
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terms are used interchangeably and have the potential to cause confusion. The paper titled 101 
‘Neurotrophic Keratitis’ from the Cambridge Ophthalmological symposium (Bonini et al., 2003) 102 
begins with the word ‘Neurotrophic keratopathy’ highlighting the inconsistency and the lack of a 103 
definitive term being assigned to the condition. ‘Keratitis’ is probably not the correct term to use 104 
even though inflammation is often associated with the pathogenesis or clinical presentation of 105 
the condition. The term ‘Neurotrophic Keratopathy’ with the acronym (NK) would be more 106 
appropriate as it encompasses the underlying nerve problem, the trophic effect on the cornea of 107 
nerve disease, both hypoaesthesia and hyper-excitable states, and does not place emphasis on 108 
‘inflammation’, which is not the primary driver of the condition. The term ‘Persistent epithelial 109 
defect’ (or its variations) though a good clinical descriptor, can be associated with a variety of 110 
non-nerve related conditions. Hence it is more appropriate as a clinical sign than the name of a 111 
disease. We propose that ‘Neurotrophic keratopathy’ be used as the definitive term to describe 112 
the condition. 113 
 114 
4. Definition 115 
 116 
The definition of Neurotrophic keratopathy (NK) has remained consistent over the last 117 
couple of decades. At the Cambridge Ophthalmological Symposium in 2003 (Bonini et al., 118 
2003), the following definition was used: “Neurotrophic keratopathy (NK) is a degenerative 119 
corneal disease induced by an impairment of trigeminal nerve. Impairment or loss of corneal 120 
sensory innervation is responsible for corneal epithelial defects, ulcer, and perforation.” The 121 
American Academy of Ophthalmology published the following definition in 2008: 122 
“Neurotrophic keratopathy (NK) is a degenerative disease of the corneal epithelium resulting 123 
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from impaired corneal innervation. A reduction in corneal sensitivity or complete corneal 124 
anesthesia is the hallmark of this disease and is responsible for producing epithelial keratopathy, 125 
ulceration and perforation (Wells and Michelson, 2008). 126 
Two recent definitions published on line by very reputable entities are presented below. 127 
The first one by Eye Wiki, a product of the American Academy of Ophthalmology, states that 128 
“Neurotrophic Keratitis (NK) is a corneal degenerative disease characterized by a reduction or 129 
absence of corneal sensitivity. In NK, corneal innervation by the trigeminal nerve is impaired” 130 
(Rabiolo and Woodward, 2017).” The other published on the Medscape is similar though more 131 
elaborate “Neurotrophic keratopathy (NK) is a degenerative disease characterized by decreased 132 
corneal sensitivity and poor corneal healing. This disorder leaves the cornea susceptible to injury 133 
and decreases reflex tearing. Epithelial breakdown can lead to ulceration, infection, melting, and 134 
perforation secondary to poor healing” (Graham, 2016). 135 
All definitions of NK describe it as a “degenerative disease” and all include “impaired 136 
corneal innervation” as the underlying pathology. The emphasis is on “sensory nerves or corneal 137 
sensation”. Recent studies have demonstrated the role of sympathetic innervation in corneal 138 
pathology (Yun et al., 2016), and the occurrence of corneal nerve hyper or aberrant regeneration, 139 
which is quite distinct from attrition or extinction of nerves in the sub-basal plexus (Al-Aqaba et 140 
al., 2011b; Al-Aqaba et al., 2012). The role of nerve sprouting and regeneration, though not 141 
resembling normal anatomy, is unclear but difficult to ignore.  In dry eye disease nerve loss 142 
followed by nerve regeneration consequent to therapy has been described (Benitez del Castillo et 143 
al., 2004; Iaccheri et al., 2017; Tuisku et al., 2008; Zhang et al., 2005). When regeneration is a 144 
component of the pathophysiology, inclusion of the term ‘degenerative disease’ in the definition 145 
may introduce a contradiction. Moreover, the underlying conditions can have inflammation, 146 
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trauma, congenital anomalies and others as the predominant manifestation. It has also been 147 
shown that partial or total sensory loss is compatible with relatively healthy corneal epithelium 148 
(Dhillon et al., 2016), though NK when clinically manifest is associated with corneal 149 
hypoaesthesia or anaesthesia. With the above points in mind we propose the following definition: 150 
“Neurotrophic keratopathy is a disease related to alterations in corneal nerves leading to 151 
impairment in sensory and trophic function with consequent breakdown of the corneal 152 
epithelium, affecting health and integrity of the tear film, epithelium and stroma”. Clinically this 153 
implies that NK is the likely diagnosis in the presence of an epithelial defect that does not heal or 154 
heals and breaks down repeatedly (changing shape and size of epithelial defect) in the presence 155 
of reduced or altered corneal trophic function and sensitivity. 156 
 157 
5. Anatomy and Physiology of Corneal Nerves 158 
5.1 Anatomy  159 
The cornea is arguably the most sensitive structure in the human body. It is 100 times 160 
more sensitive than the conjunctiva (Wells and Michelson, 2008), 40 times more than dental pulp 161 
and over 400 times more than the skin (Bonini et al., 2003). 162 
Corneal innervation is predominantly sensory, from the ophthalmic division of the 163 
Trigeminal (V cranial) nerve (Fig. 1). 1.5% (200 to 450 neurons depending on species) of the 164 
trigeminal ganglion neurons serve the cornea (Felipe et al., 1999; Launay et al., 2015; Marfurt et 165 
al., 1989).  Each neuron can support hundreds to thousands of nerve endings in the cornea 166 
(LaVail et al., 1993; Marfurt et al., 1989; Morgan et al., 1978). The nasociliary branch of the 167 
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ophthalmic division of the trigeminal nerve enters the orbit through the superior orbital fissure 168 
and is the main nerve covering the ocular surface. Two or three long ciliary nerves and a 169 
communicating branch to the ciliary ganglion arise from the nasociliary nerve before it 170 
terminates as the infra-trochlear and nasal branches (other branches are the anterior and posterior 171 
ethmoidal nerves). Six short ciliary nerves arise from the ciliary ganglion and together with the 172 
long ciliary nerves enter the suprachoroidal space by penetrating the sclera around the optic 173 
nerve. They pass anteriorly, supply the iris and ciliary body and terminate in the peri-corneal 174 
(limbal) plexus.  The limbal plexus thus has both sensory and autonomic nerves and is 175 
predominantly vasomotor in function (Marfurt et al., 2010). 176 
A mixture of sensory and autonomic nerves pass through the limbus and enter the cornea 177 
in the middle third of the stroma in a series of large, radially-oriented nerve bundles and run 178 
forward and anteriorly in a radial fashion toward the central area, giving rise to branches that 179 
innervate the anterior and mid-stroma. The posterior stroma seems to lack innervation though 180 
some investigators have noticed a sparse innervation of the corneal endothelium (Leon-Feliu et 181 
al., 1978; ten Tusscher et al., 1988; Wolter, 1957). There is a loose sub Bowman’s plexus of 182 
nerves from where fibres penetrate the Bowman’s zone, predominantly in the mid periphery of 183 
the cornea and emerge in the sub-basal (epithelium) plane where they end in single or multiple 184 
bulb-like structures which probably represent the termination and folding of the nerve sheath 185 
(Al-Aqaba et al., 2010). From this point numerous neurites emerge and spread across the surface 186 
of the cornea, in the sub-basal plane, dividing dichotomously and re-anastomosing to form the 187 
sub-basal plexus. The neurites are generally oriented such that they converge to an area between 188 
the upper two thirds and the lower one third where they form a distinct whorl pattern (Al-Aqaba 189 
et al., 2010; Patel and McGhee, 2009). Terminal branches from the sub-basal plexus pass 190 
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anteriorly into the epithelial cell layers, terminating within or in between epithelial cells (Stepp et 191 
al., 2017). A small population of axons terminates in the stroma, while others form a close 192 
anatomical relationship with stromal keratocytes and macrophages (Muller et al., 1996; Seyed-193 
Razavi et al., 2014). 194 
Autonomic innervation consists essentially of sympathetic nerves from the superior 195 
cervical ganglion (SCG). The SCG is located close to the internal carotid artery at the level of the 196 
2nd and 3rd cervical vertebrae. It receives preganglionic fibres from neurons located at the level of 197 
the 1st and 2nd thoracic spinal nerves. Postganglionic (postsynaptic) fibres from the SCG ascend 198 
in the carotid plexus around the internal carotid artery. Fibres destined for the eye leave the 199 
carotid plexus in the cavernous sinus and  enter the orbit through the superior orbital fissure as 200 
the sympathetic root of the ciliary ganglion. Some fibres directly merge with the long ciliary 201 
nerves and others pass through the ciliary ganglion, without synapse, to emerge in the short 202 
ciliary nerves. Primates including humans have little sympathetic nerve supply to the cornea 203 
(Ehinger, 1971; Sugiura and Yamaga, 1968; Toivanen et al., 1987) compared to rabbits and cats 204 
where they constitute approximately 15% of the total corneal innervation (Marfurt and Ellis, 205 
1993). Rat and cat corneas also receive parasympathetic fibres from the ciliary ganglion (Marfurt 206 
et al., 1998; Morgan et al., 1987; Tervo et al., 1979). However, this kind of innervation has not 207 
been confirmed in humans. All corneal sensory nerves derive from finely myelinated (A-δ) and 208 
unmyelinated (C) axons determined by the size and presence of myelin sheaths in the axon 209 
(Felipe et al., 1999). In the human cornea, central stromal axons are unmyelinated and run in the 210 
anterior stroma as large bundles parallel to collagen bundles. Most of the axons in these bundles 211 
are about 0.5 μm in diameter. However, few may be as large as 2.5 μm (Muller et al., 1996; 212 
Muller et al., 1997). On the other hand, more than 70% of the axons in rabbit corneas are 213 
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unmyelinated (Beuerman et al., 1983). The rest are finely myelinated axons that lose their myelin 214 
sheath within 1 mm after penetrating the cornea (Lim and Ruskell, 1978; Rozsa and Beuerman, 215 
1982; Zander and Weddell, 1951). Myelinated axons are present in the central cornea in some 216 
mammals (Rodger, 1950;  Whitear, 1960). As soon as they enter the corneal stroma, the nerve 217 
bundles lose their perineurium and continue as elongated structures running between the collagen 218 
lamellae.  219 
 220 
5.2 Physiology  221 
The physiology of corneal nerves is complex. Aspects relevant to NK are described and 222 
included herein.  Electrophysiological examinations have revealed the existence of different 223 
functional types of ocular sensory neurons, including polymodal nociceptor neurons, cold 224 
thermoreceptor neurons, and selective mechano-nociceptor neurons (Belmonte et al., 2004a; 225 
Belmonte et al., 2004b). 226 
The majority of the sensory nerve fibres innervating the cornea are polymodal 227 
nociceptors which are activated with near-noxious or noxious mechanical energy, heat, chemical 228 
irritants, endogenous chemical mediators released by damaged corneal tissue, and by 229 
inflammatory cells (Belmonte et al., 1991; Belmonte and Giraldez, 1981; Gallar et al., 1993; 230 
MacIver and Tanelian, 1993). When the stimulus causes tissue injury severe enough to trigger 231 
local inflammation, their threshold for activation decreases, and the impulse discharge evoked by 232 
suprathreshold stimulation increases. So called “sensitization” develops and may be associated 233 
with allodynia (pain evoked by innocuous stimuli), hyperalgesia (enhanced pain in response to 234 
noxious stimuli) and spontaneous pain (Stapleton et al., 2013). Reflex tear secretion caused by 235 
corneal stimulation seems to be chiefly due to activation of corneal polymodal nociceptors 236 
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(Acosta, Peral, 2004). The transient receptor potential (TRP) cation channels subfamily V 237 
member 1 (TRPV1) plays an important role in sensory transduction in polymodal nociceptors. It 238 
is expressed in intraepithelial nerve terminal endings in the corneal epithelium (Alamri et al., 239 
2015; Guo et al., 1999; Murata and Masuko, 2006) and is activated by capsaicin, low pH, 240 
noxious heat and hyperosmolarity (Caterina et al., 1997; Davis et al., 2000; Straub, 2014). Acid-241 
sensing ion channels (ASICs) and TRP cation channel subfamily A member 1 (TRPA1) also 242 
appear to contribute to chemical sensitivity of corneal polymodal nociceptors (Bandell et al., 243 
2004; Bautista et al., 2013; Callejo et al., 2015).  244 
The neuropeptides contained in some polymodal receptors (substance P and calcitonin 245 
gen-related peptide – CGRP) maintain corneal homeostasis and integrity by promoting corneal 246 
epithelial cell proliferation, migration, adhesion and differentiation (Garcia-Hirschfeld et al., 247 
1994; Reid et al., 1993; Tran et al., 2000). Corneal epithelial cells in turn, release soluble factors 248 
(e.g. NGF and GDNF) that promote neurite extension and survival (Chan and Haschke, 1981; 249 
Lambiase et al., 2000). Furthermore, the lacrimal gland provides growth factors and nutrients 250 
and in turn, its function is influenced by sensory nerves. About 20-30% of peripheral axons 251 
innervating the cornea are selective mechano-nociceptors, which respond only to mechanical 252 
stimuli at an order of magnitude close to that required for corneal epithelial damage (Belmonte et 253 
al., 1991; MacIver and Tanelian, 1993). These mechano-nociceptors are probably responsible for 254 
the acute, sharp pain sensation induced by touching or scratching the corneal surface. Piezo2, a 255 
newly identified mechanically sensitive ion channel is present in about 30% of corneal sensory 256 
neurons in the trigeminal ganglion, but has not been described yet in the intraepithelial nerve 257 
terminals (Alamri et al., 2015; Bron et al., 2014). Cold thermoreceptors represent 10-15% of the 258 
total population of corneal sensory neurons (Belmonte et al., 2017). They change their activity 259 
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with both cooling and heating as well as with changes in osmolarity (Carr et al., 2003; Gallar et 260 
al., 1993; Parra et al., 2014; Quallo et al., 2015). Their activity is modulated by inflammation, 261 
which reduces their impulse activity as well as by peripheral injury that increases firing 262 
frequency (Acosta et al., 2013). The TRP subfamily member M8 is a cation channel that is 263 
important for cold sensation. It is activated by cooling, menthol, and osmolality values greater 264 
than 340 mOsm. (McKemy et al., 2002; Parra et al., 2010; Peier et al., 2002; Quallo et al., 2015). 265 
In the rabbit cornea, specific populations of c-fibers exist which are stimulated by acetylcholine 266 
possibly acting via a neuronal nicotinic receptor (Tanelian, 1991). 267 
Nerve growth factor (NGF), epidermal growth factor (EGF), glial derived neurotrophic 268 
factor (GDNF) as well as brain derived neurotrophic factor (BDNF) are the main agents of an 269 
epithelial-nerve cross talk which plays a fundamental role in corneal wellbeing and healing 270 
(Muller et al., 2003). NGF, GDNF, their receptors TrkA and GFRa-1, as well as BDNF may also 271 
play an important role in maintaining corneal epithelial stem cells in the limbus (Qi et al., 2007). 272 
In addition, NGF seems to facilitate innervation of perivascular nerves to regulate blood flow in 273 
corneal neovascularization (Matsuyama et al., 2017). Recent evidence indicates, that significant 274 
and complex interactions exist between the nervous and immune system. Primary sensory 275 
neurons seem to be involved in maintaining the cornea’s immune privilege (Belmonte et al., 276 
2017). Moreover, peptidergic polymodal nociceptor terminals with their sensory neuropeptides 277 
substance P and CGRP contribute to the inflammatory response following tissue injury 278 
(neurogenic inflammation) (Belmonte et al., 2004a): CGRP has immunosuppressive effects, 279 
while substance P acts as a potent pro-inflammatory neuropeptide (Micera et al., 2006; Reynier-280 
Rebuffel et al., 1994). Fractalkine (FKN, CX3XL1), produced by primary sensory neurons, plays 281 
an important role in the maintenance of corneal well-being, and disturbances in FKN/CX3CR1-282 
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signalling may also result in corneal inflammation (Clark, 2014). NGF is a constitutive molecule 283 
present and produced in normal human corneas and important for the development and 284 
maintenance of peripheral sensory neurons. NGF and/or NGF-receptors TrkA and p75NTR are 285 
expressed in many corneal tissues including epithelium, endothelium, keratocytes and nerves, as 286 
well as by bone marrow (BM) derived cells present in the cornea (Lambiase et al., 2000; Sarkar 287 
et al., 2013). Tear NGF is increased after both photorefractive keratectomy and laser in situ 288 
keratomileusis (Lee et al., 2005). In addition, some semaphorins such as Sema7A and VEGF-A 289 
act as neurotrophic factors in the cornea and are able to influence inflammatory events (Li et al., 290 
2011; Namavari et al., 2012; Takamatsu and Kumanogoh, 2012). T-cell-dependent inflammation 291 
involving IL-17, neutrophils, platelets, and VEGF-A seems to promote corneal nerve 292 
regeneration (Li et al., 2011; Namavari et al., 2012; Takamatsu and Kumanogoh, 2012). 293 
In a healthy eye, bidirectional communication between nerves and the immune system 294 
forms a negative feedback loop that keeps both systems in check (Belmonte et al., 2017). Minor 295 
insults to the ocular surface are rapidly healed within a continuous trophic environment 296 
maintained by corneal innervation and the tear film (Mathers, 2000; Stern et al., 1998).   297 
 298 
6. Incidence and prevalence  299 
 300 
To determine the prevalence and incidence of a disease it is necessary to first agree upon a 301 
definition (DEWS report 2007). With regard to NK, as highlighted above, the definition has not 302 
changed for more than 15 years. In the context of the prevailing definition, NK has been 303 
classified as a rare/orphan disease (ORPHA137596) affecting 5 individuals or fewer in 10,000. 304 
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NK requires a fresh and joined approach by all stakeholders to enable effective treatment in the 305 
context of all options available. 306 
There is a paucity of information in the literature regarding the prevalence and incidence of 307 
NK. The best evidence available (Sacchetti and Lambiase, 2014) is based on extrapolation from 308 
the two most common conditions associated with NK, which are herpetic keratitis (incidence of 309 
1.22/10,000) and post-surgical nerve damage (incidence of 0.02/10,000); as being below 310 
1.6/10,000. More specifically, NK develops in an average of 6% of herpetic keratitis cases, 311 
which has a prevalence of 149/100,000 (Labetoulle et al., 2005) and in 12.8% of herpes zoster 312 
keratitis cases, which has a prevalence of 26/100,000 (Dworkin et al., 2007).  Other than herpetic 313 
keratitis, the most common cause of NK is neurosurgical intervention to treat trigeminal 314 
neuralgia that damages the trigeminal nerve (post-surgical incidence of 2.8%), which has a 315 
prevalence of 1.5/10,000, and an estimated prevalence of NK after neurosurgical procedure of 316 
0.02/10,000 (Bhatti and Patel, 2005). Unfortunately, no epidemiological data can be found in the 317 
literature for a number of other common conditions known to cause NK such as chemical burns, 318 
diabetes, contact lenses and less frequent causes such as space occupying intracranial masses, 319 
multiple sclerosis and leprosy. 320 
Geerling et al. (unpublished observations, 2017) in a retrospective case series from a 321 
subspecialist  corneal clinic in Germany identified 38 eyes of 35 patients (17 males and 18 322 
females with a mean age of 67 years) with NK over a two year period (2015-2016). They 323 
searched for patients, who were treated with autologous serum eye drops, amniotic membrane 324 
transplantation, emergency corneal grafting or a combination thereof (commonly employed 325 
treatments for moderate to severe NK).  40.6% of emergency corneal grafts (13 out of 32), 15% 326 
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of amniotic membrane transplantations (28 out of 187) and 17.9% of autologous serum 327 
treatments (7 out of 39) were related to NK. 328 
 Although dry eyes are a feature of NK, dry eye disease and NK are different clinical 329 
entities. Some convergence is seen however, when laser refractive surgery is considered as a 330 
cause of neuropathic dry eye (Chao et al., 2014). The incidence of neuropathic dry eye following 331 
laser in-situ keratomileusis is estimated to be between 2 to 5% of Caucasian patients, rising to 332 
around 28% in Asians (Albietz et al., 2005; Azuma et al., 2014).   333 
 334 
7. Aetiology and Pathogenesis of Neurotrophic Keratopathy 335 
7.1 Etiology of Neurotrophic Keratopathy 336 
Any persistent alteration of the corneal sensory innervation interfering with the function 337 
of the post-ganglionic fibres can cause  NK (Sacchetti and Lambiase, 2014). (Fibres projecting 338 
from cortical/spinal nuclei to the trigeminal ganglion are pre-ganglionic and those projecting 339 
from the ganglion to the ocular surface are post-ganglionic). The common causes of severe NK 340 
are corneal herpes infections,  ocular surface thermal and chemical burns, contact lens misuse 341 
and cranial neurosurgery. A number of events and ocular and systemic conditions can 342 
chronically affect the functioning of corneal nerves inducing NK. Unpublished observations 343 
[Figueiredo G, Baylis O, Lako M, Figueiredo FC]  from a prospective phase II clinical trial in the 344 
UK on treatment of unilateral ocular surface burns related total limbal stem cell deficiency 345 
(LSCD) with ex vivo expanded autologous limbal stem cell transplantation demonstrated that that 346 
all 23 patients studied also had NK in the affected eye.  The mean age of patients was 44.7 years 347 
(range 24-81, SD 14.19). The mean Cochet-Bonnet aesthesiometry measurement was 9.13 (range 348 
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0-30, SD 9.73) in the LSCD/NK eyes and 59.13 (range 50-60, SD 2.881) in the fellow normal 349 
eyes. The difference between the LSCD/NK and fellow eyes was statistically significant 350 
(p<0.0001, Wilcoxon rank test). A summary of the common causes of ocular surface nerve 351 
damage is given in table 2. 352 
 353 
7.2 Pathogenesis of NK 354 
In animal models, ocular nerve injury causes swelling of the squamous epithelial cells, loss of 355 
cell surface microvilli, abnormal basement production, acceleration of sloughing and loss of cells 356 
in to the tears, with epithelial thinning and breakdown (Mishima, 1957; Alper, 1975; Beuerman 357 
and Schimmelpfennig, 1980). The number of mitoses is diminished and as a consequence, 358 
epithelial healing is impaired leading to recurrent erosions and ulcerations (Bonini et al., 2003). 359 
Denervation of the cornea limits the extent and increases the duration of wound closure (Wilson 360 
and Ambrosio, 2001). In a model of NK created by surgical amputation of the trigeminal 361 
ganglion in albino rabbits, Akari et al demonstrated a delayed rate of healing, fewer desmosomes 362 
and excessive exfoliation of epithelial cells leading to persistent epithelial defects (Araki et 363 
al.,1994). 364 
 365 
Many theories have been proposed to explain the pathogenesis of NK, including, 366 
desiccation of the corneal surface due to diminished lacrimal secretions as  tear secretion is nerve 367 
stimuli dependent (Belmonte and Gallar, 2011); impaired corneal sensitivity leading to 368 
diminished protective blink reflexes, abnormal epithelial cell metabolism with subsequent failure 369 
to resist the effects of trauma, drying, and infection; and the loss of trophic influences provided 370 
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by corneal nerve fibres (De Haas, 1962; Duke-Elder and Leigh, 1965; Heigle and Pflugfelder, 371 
1996; Paton, 1926; Wilson and Ambrosio, 2001). In most cases it is probably a combination of 372 
these factors, with a neurotrophic deficit playing a major role.  373 
The reduced secretion of tear fluid and the loss of vitality of the epithelial cells can cause 374 
a reduction in the presence of neurotrophins on the ocular surface, in particular NGF, which is a 375 
neurotrophin essential to the development and survival of sympathetic and sensory neurons, 376 
and for trophic support after neuronal injuries (Sacchetti and Lambiase, 2017). It is normally 377 
present in the healthy cornea, where it regulates the proliferation and differentiation of 378 
epithelial cells. NGF also appears to be involved in epithelial and stromal interactions that 379 
induce stromal healing and remodelling.  A reduced availability of NGF will result in 380 
impaired nerve and cornea functions (Chen et al., 2014; Di et al., 2017; Park et al., 2016). 381 
Reduced mitosis would lead to a slowing of or a dysfunction in the centripetal movement of 382 
cells from the limbus, thus affecting the cells in the centre of the cornea. As the cells here 383 
age, their ability to hold the tear film on the surface also reduces. This combined with the 384 
effect of the altered quality and amount of tear fluid may reduce the ability of the tear film 385 
to cushion the shearing stress of lid movements. The central cornea would then be most 386 
vulnerable and this can explain the central location of epitheliopathy at onset of NK and the 387 
subsequent ulcer. Reduced tear production is a major cause of decreased tear clearance with 388 
consequent accumulation of toxic agents and pro-inflammatory cytokines on the ocular surface, 389 
which may also be a contributing factor. 390 
 Excessive and rapid evaporation of tears from the ocular surface could be a source of 391 
epithelial keratopathy in dry eyes. Rapid evaporation causes a drop in corneal temperature, 392 
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which in turn will trigger acute  and repeated stimulation of cold nerve sensors at the corneal 393 
surface. Over time, continuous stimuli will change the thermal sensor function into nociceptor 394 
(pain) sensor (Belmonte et al., 2009).  Stimulation of peripheral nociceptors leads to the release 395 
of a variety of substances that can further stimulate the nociceptors and evoke release of  pro-396 
inflammatory mediators such as Substance P, CGRP, Neurokinin A (NKA), and Endothelin-3 397 
(ET-3), and induce neurogenic inflammation.   398 
 Anatomical studies have shown a direct apposition of nerve terminals with dendritic 399 
cells, which are cells of the innate immune system.  Neuropeptides released from nociceptors can 400 
induce degranulation or cytokine production in these cells.  CGRP-containing nerve fibres are 401 
intimately associated with Langherans cells (LC) in human epidermis and CGRP is found at the 402 
surface of some LC.  In three functional assays CGRP inhibited LC antigen presentation. These 403 
findings indicate that CGRP may have immunomodulatory effects in vivo and suggest a locus of 404 
interaction between the nervous system and immunological function (Hosoi et al., 1993). 405 
 Infrequent blinking associated with NK can thus induce and sustain an inflammatory 406 
environment and perpetuate epithelial keratopathy.  Furthermore, there is some evidence 407 
suggesting that healthy epithelial cells of the cornea may work as Schwann cells on the local 408 
denuded nerve fibres (Stepp et al., 2017). Loss of epithelial support will make nerves vulnerable 409 
to damage and improper function building a vicious cycle of evaporation - excessive stimulation 410 
-  neurogenic inflammation – epithelial damage - nerve hyper/ improper activity – inflammation. 411 
Evaporation from the tear film is not balanced by corresponding increase in tear secretion thus 412 
leading to a hyperosmotic environment, which induces cell apoptosis and inflammation with an 413 
increased expression of matrix metalloproteinases (MMP) initiating a cascade of events which 414 
perpetuate and worsen the condition (Baudouin et al., 2013). These collagenolytic enzymes 415 
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(especially MMP-2 and -9) are produced by corneal epithelial and stromal cells themselves 416 
(Geerling et al., 1999).  An imbalance between the  activators and inhibitors of MMPs is the 417 
main driver for progression and chronicity of the stromal ulceration and collagen melting, which 418 
can eventually lead to corneal perforation and loss of vision (Fini et al., 1992). Corneal epithelial 419 
damage also impairs its ability to maintain a difference in electric potential between the outer 420 
and inner surfaces. Loss of the electro negative repulsive charge favours bacterial adherence. 421 
This combined with the loss of a whole host of antimicrobial peptides (Mohammed et al., 2017) 422 
that are normally present in the tear film and actively secreted by the epithelium, favours 423 
microbial invasion and infection. Infection in turn augments stromal melting.  424 
The impact of preservatives on the ocular surface, especially benzalkonium chloride 425 
(BAK) used in topical eye medications, deserves special mention. BAK is a tensioactive and 426 
cytotoxic compound widely used as preservative in ophthalmic solutions. It is known to induce 427 
pro-inflammatory and pro-apoptotic effects proportional to its concentration and is responsible 428 
for multiple effects on the ocular surface, specifically the induction of dry eye and chronic 429 
inflammatory changes (Baudouin et al., 2010). BAK has also been shown to be neurotoxic 430 
(Sarkar et al., 2012), causing corneal hypoesthesia and nerve damage (Labbe et al., 2012; 431 
Martone et al., 2009). Moreover BAK may severely affect corneal wound healing, delaying 432 
corneal epithelial wound closure in animal models, even below the concentration (0.01%), found 433 
in most ophthalmic solutions (Kossendrup et al., 1985; Nagai et al., 2010; Sharma et al., 2011). 434 
In vivo and in vitro models showed the negative impact of BAK-containing solutions on 435 
damaged corneas (Liang et al., 2012). These models offer easy and reliable investigations of the 436 
effect of substances on the wound healing process. In vitro wound-healing assays using corneal 437 
cell monolayers involve the making of a standardized ‘scratch’ in the monolayer with a sterile 438 
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micropipette tip under an inverted microscope (Fig. 21). Cell proliferation as well as rate and 439 
extent of wound closure are easily followed and documented, allowing reliable investigations 440 
and comparisons on drug toxicity profiles. Although most active compounds used in glaucoma 441 
like beta-blockers or prostaglandin analogs are found to be almost neutral (Liang et al., 2012), 442 
BAK reliably shows concentration-dependent delay in wound healing, with concentrations as 443 
low as 0.001% being toxic and delaying wound closure.  These models however do not take into 444 
account the additional effects of BAK on tear film, goblet cells, corneal nerves and inflammatory 445 
cells (Baudouin et al., 2010).  Any non-healing corneal epithelial defect in an eye receiving 446 
potentially toxic compounds like preservatives, antibiotics, steroids or non-steroidal anti-447 
inflammatory drugs should be considered as a possible iatrogenic consequence of therapy and 448 
cessation of medication should be considered as a first step before embarking on elaborate 449 
management regimes (Gomes et al., 2017). 450 
 The role of the conjunctiva in the pathogenesis of NK is not clear even though it 451 
undergoes significant changes during the disease process including a decrease of goblet cell 452 
density and loss of cell-surface microplicae. Gilbard and Rossi (Gilbard and Rossi, 1990) 453 
demonstrated that  although the conjunctival changes in NK were consistent with increase in tear 454 
film osmolarity and surface changes as seen in dry eye disease, the corneal changes observed 455 
with denervation, including slit-lamp findings, morphologic changes and decreases in glycogen, 456 
were too severe and rapid in onset to be accounted for by osmolarity alone.  457 
 With greater degree of hypoaesthesia and anaesthesia, the patient has almost no 458 
symptoms. Medical attention is delayed until the disease progresses to a stage where vision is 459 
affected.  However, the hypoaesthesia may affect only the denuded area (ulcer) with sensations 460 
persisting in the surrounding cornea. Paradoxically, NK can present with symptoms of 461 
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neuropathic corneal pain as seen after Herpes zoster ophthlamicus. There is likely to be a 462 
spectrum from increased sensitivity and decreased threshold (hyperaesthesia) to absence of 463 
corneal sensations, with the former leading to the latter as the disease progresses.  464 
 NK related to herpes related keratitis is an enigma. Recurrent HSK results in persistent 465 
epithelial defects in the cornea ipsilateral to the affected trigeminal pathway. This is associated 466 
with hyperosmolarity, reduced tear break up time, reduced tear secretion (Schirmer I test) and 467 
reduced sensations not only in the affected eye but also in the unaffected eye (Rousseau et al., 468 
2015; M'Garrech et al., 2013; Jabbarvand et al., 2015). Unilateral herpes simplex and herpes 469 
zoster keratitis is associated with bilateral loss of corneal nerve receptors and dendritic cell 470 
infiltration (Hamrah et al., 2010; Hamrah et al., 2013; Cavalcanti et al., 2018) .The findings are 471 
mirrored in studies on rabbits with unilateral trigeminal axotomy, wherein bilateral loss of 472 
corneal nerves and immune cell infiltration was demonstrated (Yamaguchi et al., 2016;  473 
Yamaguchi et al., 2013). This suggests that unilateral affection of the (central) trigeminal 474 
pathways could trigger bilateral responses probably via neurogenic inflammation. In humans, 475 
though clinical manifestations are predominantly unilateral it is possible that subclinical NK is 476 
present in the other eye as well, in some cases. Whether amelioration of signs and symptoms by 477 
treatment of the affected eye leads to resolution of changes in the other eye remains to be seen.   478 
 479 
7.3 Natural History of NK 480 
When cornea sensitivity is impaired or lost, a sequence of events is triggered at the ocular 481 
surface leading to NK and its consequences (Fig. 32).  482 
a. Tear secretion is reduced or abolished, the tear film is thinner and unstable. Mucin 483 
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distribution over the ocular surface is altered and irregular. The composition of tears 484 
changes with regard to growth factors, cytokines, antimicrobial peptides and ions 485 
adversely affecting epithelial homeostasis. Its physical ability to protect against lid 486 
shearing forces is diminished.  487 
b. Due to lack of trophic neuro-mediators, epithelial cells mitosis and maturation at the 488 
limbus and centripetal migration are slowed down. This results in the accumulation of 489 
older, less vital, pre-exfoliating cells in the centre of the cornea with poor ability to be 490 
wetted, which can be easily damaged by friction with the lids during blinks.                491 
Tear film changes and lack of trophic support may lead to epithelial irregularity and 492 
grayish appearance which may affect the quality of vision. 493 
c. Continuous epithelial damage results in chronic epithelial instability, with loss of 494 
effective tight junctions and zonulae occludens, and increased risk of bacterial adhesion 495 
and infection. 496 
d. With time, the tear film alteration, epithelial pathology and reduced ability to provide 497 
new cells, all combine to worsen the epithelial damage leading to  an  epithelial defect 498 
characterized by its central position and by the presence of rolled borders made of cells 499 
that are unable to adhere to the basement membrane possibly covered by denatured 500 
mucins or bacteria, which are no longer cleared by adequate tear production.   501 
e. Surface dryness, inflammatory cytokines and local epithelial damage leaves the 502 
underlying stroma open to the destructive activity of MMP resulting in stromal melts 503 
(Pflugfelder et al., 2005). 504 
f. The extent and progression of stromal damage is determined by the balance between 505 
activators and inhibitors of the proteases. Attempts at healing lead to unsuitable 506 
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collagen deposition, with irregular scar formation, loss of transparency and visual 507 
function.  508 
g. Unchecked disease and ongoing metalloproteinase activity leads to perforation 509 
(Chotikavanich et al., 2009). 510 
h. Eventually functional and anatomical loss of the eye occurs. 511 
 512 
8. Clinical presentation and classification 513 
Patients with NK will present in the early stage of the disease with symptoms of dryness, 514 
photophobia, and inability to read for a prolonged period of time due to epithelial changes and 515 
instability (see pathogenesis), impaired quality of vision and reduced blink.  Symptoms are 516 
usually worse in the morning or in the presence of aggravating factors such as air conditioning, 517 
air travel, draught of hot air from car heating or prolonged use of some computers (draught of hot 518 
air from computer fans and reduced blinking associated with mental concentration) (Dua et al., 519 
2014). Paradoxically, with worsening or severe disease, the symptoms of pain and discomfort 520 
may be less or absent due to sensory dullness related to hypoaesthesia or anaesthesia of the 521 
cornea.  Symptoms of visual impairment appear when the central cornea is significantly 522 
involved. Clinical signs relate to those associated with the underlying condition and those due 523 
NK, usually a combination of the two. 524 
 525 
8.1 Signs related to NK 526 
 527 
Early signs are similar to those of dry eye with rapid tear-break up time, narrow tear meniscus 528 
and inferior one third conjunctival and corneal punctate staining with fluorescein (superficial punctate 529 
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keratitis SPK). The blink rate can be reduced and irregular (normal 17 blinks per minute) (Bentivoglio et 530 
al., 1997). The cornea reflex (lustre) becomes dull and the epithelium appears cloudy with epithelial 531 
irregularities. In NK related to laser refractive surgery (Ocular surface syndrome) (Alio et al., 2007; 532 
Ambrosio et al., 2008), SPK is centrally located and can wax and wane (Fig. 43 a-c). With increasing 533 
severity, the epithelial erosions coalesce and become larger (coarse erosions) and a frank epithelial defect, 534 
usually centrally located, appears (Fig. 43 d-f). Attempts at healing of the defect are slow and often 535 
incomplete. The area of the defect changes as the epithelium heals and breaks down repeatedly. 536 
Eventually the defect becomes permanent (persistent epithelial defect, PED) with smooth or rolled and 537 
opaque edges. The epithelium around the perimeter of the defect is loosely attached to the underlying 538 
Bowman’s layer as evidenced by the sub-epithelial seepage of fluorescein dye, beyond the edge of the 539 
defect.  The exposed stroma is vulnerable to the effect of proteases resulting in melting, that can lead to 540 
perforation (Fig. 43 g-i). The ulcer is usually sterile however secondary microbial infection can occur 541 
which can lead to rapid progression of melting and perforation. (Fig. 54). Stromal involvement can also 542 
manifest as edema, striae and Descemet’s folds. Cells in the anterior chamber can be seen and frank 543 
hypopyon should be carefully evaluated and followed since it can be sterile or a sign of secondary 544 
infection. In vivo confocal microscopy examination, in the presence of frank corneal hypoaesthesia, can 545 
show an intact sub-basal plexus (pre-ganglionic affection of the Vth nerve) with a relatively better 546 
prognosis (Dhillon et al., 2016). In the majority of cases however, the sub-basal plexus is deficient. 547 
Corneal vascularization is variable in its occurrence and severity. NK itself can cause 548 
stromal vascularization but wide variations related to the underlying cause, can be seen. Some 549 
infections like with acanthamoeba cause little vascularization whilst herpes virus infections 550 
cause the most (Faraj et al., 2016). Ocular surface inflammation maybe obvious as conjunctival 551 
hyperemia or could be completely absent. 552 
 553 
8.2 Signs related to underlying disease 554 
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 555 
Signs related to the underlying cause could manifest as lagophthalmos or reduced blink 556 
reflex, signs of previous herpetic keratitis with scarring and vascularization or patches of iris 557 
atrophy, lattice or granular dystrophy, enlarged beaded corneal nerves, scarring from previous 558 
corneal infections, limbal stem cell deficiency, advanced diabetic retinopathy or  pan-retinal 559 
photocoagulation. Optic disc swelling or atrophy may suggest orbital or cranial lesions. Reduced 560 
or absent sensation in the dermatomes supplied by the trigeminal nerve which may be associated 561 
with other cranial nerve affection may give clues to the underlying cause.  Seventh cranial nerve 562 
palsy may affect the prognosis of the disease from corneal exposure due to lagophthalmos and 563 
reduced blink reflex and can be modified by the presence or absence of a good Bell’s 564 
phenomenon. 565 
 566 
8.3  Classification 567 
Traditionally NK has been classified into 3 stages as described by Mackie (Mackie, 568 
1995). 569 
Stage 1 of neurotrophic keratopathy demonstrates the following: 570 
• Rose Bengal staining of the inferior palpebral conjunctiva (lissamine green is now the 571 
standard dye used instead of rose Bengal) 572 
• Decreased tear breakup time  573 
• Increased mucous viscosity  574 
• Punctate corneal epithelial fluorescein staining  575 
Stage 2 is characterised by: 576 
• Epithelial defect - Usually oval and in the superior cornea  577 
• Defect surrounded by a rim of loose epithelium  578 
• Edges may become smooth and rolled  579 
• Stromal swelling with folds in the Descemet’s membrane  580 
• Sometimes associated with anterior chamber inflammatory activity 581 
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Stage 3 is characterised by:  582 
• Stromal lysis/melting  583 
• May result in perforation 584 
Dryness and visual aberrations are the main symptoms of NK and reduced or absent corneal 585 
sensations, the main and arguably the pathognomonic clinical sign. However, with current 586 
understanding of corneal nerve pathology using in vivo confocal microscopy and post-mortem 587 
whole mount staining of corneal pathology it is evident that aberrant re-generation and hyper-588 
regeneration of nerves also occurs, which could by inference lead to corneal hyper-aesthesia and 589 
account for the occurrence of symptoms that are out of proportion to the clinical signs (Al-Aqaba 590 
et al., 2011b; Al-Aqaba et al., 2012; Wolter, 1964, 1966). This however is usually seen in some 591 
cases in early disease and current available methods of evaluation do not allow the assessment of 592 
increased sensitivity. Reduced sensitivity and the consequences thereof constitute the classical 593 
manifestation of NK. Direct imaging of nerves has enabled a degree of quantification based on 594 
nerve density, tortuosity, thickness, reflectivity and aberrations such as looping, coiling, 595 
irregularity in diameter, presence of ‘growth cones’ and truncation (dead ends). It has also been 596 
demonstrated that nerve anomalies can be localised to some parts of the cornea whilst others can 597 
have normal physical appearance of nerves and their distribution. It is not clear whether altered 598 
sensitivity is restricted to the areas of nerve anomalies or more generally reflected in the cornea. 599 
Nevertheless, it is good practice to test sensations in the centre and in the peripheral four 600 
quadrants. Patient symptoms appear to be more generalised, with no specific corneal/ocular 601 
surface localisation, regardless of the location of nerve anomaly. 602 
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Although the Mackie classification has been in vogue for a number of years, we propose the 603 
following adaptation, which would be more clinically relevant and indicate severity and 604 
prognosis. Examples are given in figure fourthree. 605 
• Mild [Epithelial changes only without epithelial defect]: Epithelial irregularity without 606 
frank epithelial defect/; tear film instability and symptoms (hyper-aesthesia) with reduced 607 
or absent sensations in one or more quadrants of the cornea. 608 
• Moderate [Epithelial defect without stromal defect]: Frank persistent epithelial defect and 609 
corneal hypo-aesthesia/anaesthesia. 610 
• Severe [Stromal involvement]: Stromal involvement from corneal ulcer to lysis to 611 
perforation, with corneal hypo-aesthesia/anaesthesia. 612 
Epithelial disturbance, frank non-healing epithelial defect and stromal lysis usually but 613 
not necessarily follow sequentially (Figs. 65-87) . All other clinical signs of NK are variable and 614 
do not appear or progress sequentially as is often determined by the underlying condition for 615 
example in a case of chemical burn the patient may present with severe NK without having 616 
progressed through NK of mild and moderate severity. It is important to understand the 617 
difference between an abrasion and an ulcer as both are technically ‘epithelial defects’. Abrasion 618 
implies the rubbing or scraping away of cells from the surface of an area of the cornea, skin or 619 
mucous membrane; whereas an ulcer is a breach of the continuity of the epithelium of any of the 620 
above mentioned tissues, due to sloughing related to inflammation and tissue necrosis. Abraisons 621 
generally heal rapidly while ulcers take longer to heal, festering as ‘non-healing epithelial 622 
defects’. 623 
 624 
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9. Diagnosis and Differential diagnosis 625 
 626 
Diagnosis of NK is based on the clinical interpretation of the history, general examination of 627 
the patient, slit lamp examination of the eye and findings of some diagnostic tests. Clinical 628 
examination and tests are directed towards features of NK and of any possible underlying 629 
condition. 630 
9.1 Ocular symptoms 631 
Symptoms of NK are elaborated in the section on clinical features and should be 632 
specifically explored as the presenting symptoms of NK can vary according to the 633 
severity of the disease. Other symptoms such as dryness, photophobia, lacrimation and 634 
visual disturbance or impairment can be present and should be explored and documented. 635 
There is lack of correlation between symptoms and signs. Neuropathic corneal pain can 636 
be a presenting feature and severe corneal signs can be present with disproportionally 637 
minimal pain. 638 
 639 
9.2 Clinical History 640 
Patients often have a history of features related to an underlying condition (table 2). 641 
Previous hospital visits for ophthalmic and non-ophthalmic consultations, previous ocular or 642 
brain surgery, ocular or head trauma, use of topical medication (specifically preserved eye drops) 643 
and systemic medication (eg. neuroleptics and antipsychotic drugs). Systemic chronic conditions 644 
such as diabetes and multiple sclerosis can be present. Topical anaesthetic misuse is often missed 645 
unless suspected in individuals with specific professions (eg. welders, metal workers).    646 
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9.3 Examination 647 
9.3.1 Neurological Examination 648 
This includes assessing cranial nerve function, which may help to localize trigeminal 649 
damage. Concurrent abnormalities of the third cranial nerve with sixth cranial nerve may indicate 650 
damage in the cavernous sinus or localize an intracranial aneurysm. Pupillary abnormalities may 651 
indicate the status of third nerve, as well as defects, in the sympathetic innervation of the iris. 652 
The presence of an afferent papillary defect in association with corneal hypoesthesia would 653 
localize the lesion to the intra-conal orbit. Pupil reactions consistent with Adie’s pupil have also 654 
been associated with alterations in corneal sensation. 655 
Abnormalities of the 7th & 8th cranial nerve may indicate damage from acoustic 656 
neuroma or neuro-surgery. Damage to 7th nerve may can lead to exposure of the ocular surface 657 
due to lagophthalmos, which will worsen prognosis of patients with NK especially in the absence 658 
of Bell’s phenomena.  659 
9.3.2 Ophthalmic Examination 660 
 9.3.2.1 External exam (eyelids and conjunctiva)Eyelids 661 
Eyelid function is critical to the prognosis of neurotrophic keratitis and progression of 662 
advanced disease. Lid features to note are ectropion, entropion, misdirected lashes or ptosis 663 
(oculomotor nerve damage or mild ptosis in the presence of corneal infection). Lid scarring may 664 
be present secondary to removal of periocular infiltrative tumors or chemical or thermal burns. 665 
The conjunctivae in NK patients generally show a lack of conjunctival injection i.e. ‘white’ eye. 666 
The presence of ‘red eye’, however, would indicate the presence of co-existing inflammation 667 
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usually related to secondary infection. Subconjunctival fibrosis may be present, which could be 668 
associated with chronic autoimmune disease and/or severe dry eye.  669 
9.3.2.2  Slit lamp examination  670 
Examination of the cornea in NK with the slit lamp may reveal a spectrum of changes, as 671 
described in the section on ‘Clinical features’. Other corneal changes which may indicate 672 
previous infections or recurrent corneal ulceration should be noted, such as the presence of 673 
vascularization and/or scarring. Keratitis related Herpes virus infection is the commonest cause 674 
of corneal vascularization (Faraj et al., 2016). Anterior chamber examination may reveal flare, 675 
keratic precipitates, cells or frank hypopyon from active anterior uveitis, which may result from 676 
non-viral corneal infection or inflammatory reaction from herpetic kerato-uveitis. Iris 677 
examination may show sectoral transillumination indicating iris atrophy secondary to herpes 678 
kerato-uveitis/iris pigment epithelialitis.  679 
9.4 Vital Staining 680 
 Fluorescein and lissamine green dyes are useful in assessing subtle changes in the 681 
epithelium (mild NK) and frank epithelial defects (moderate and severe NK).  As tear film 682 
anomalies are integral to the pathophysiology of NK, tear assessment is important. Besides other 683 
tests such Schirmer’s test, both these vital dyes are useful in assessing ‘dry eye’ signs such as 684 
tear meniscus height, tear breakup time and punctate corneal and conjunctival erosions. 685 
Assessment of tear film osmolarity is considered to be important in dry eye disease but its role in 686 
NK is not clear (Belmonte et al., 2017).  Ocular fundus examination may reveal diabetic 687 
retinopathy, optic nerve pallor (multiple sclerosis) or swelling from an intracranial neoplasm. 688 
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The above account illustrates that, as with any ocular assessment, with NK too, it has to be 689 
thorough and complete and not restricted to the cornea or ocular surface. 690 
9.5 Diagnostic tests 691 
9.5.1 Corneal Sensation 692 
Assessment of corneal sensation is fundamental to the diagnosis of NK. The algorithm 693 
for diagnosis is given in the diagram (Fig. 98). Clinically, corneal sensation is assessed by using 694 
a ‘wisp’ of cotton applied to both corneas (Fig. 109a). Patient’s reaction is noted and compared 695 
between the eyes. NK patients typically show reduced blinking/sensation to the stimulus. 696 
Corneal sensation is reduced or normal, if it is normal then NK unlikely. Some authors have 697 
stated that an absence of the nasal-lacrimal tearing reflex along with ipsilateral loss of sensation 698 
in the nasal mucosa presents a high risk for subsequent neurotrophic corneal ulceration, so there 699 
may be a basis for testing this.  700 
Corneal sensation can be (semi)quantitively measured by the Cochet-Bonnet 701 
aesthesiometer or the Belmonte non-contact gas aesthesiometer (BNGA) (Fig. 109b and 109c). 702 
The former is a contact instrument and the latter is not. With the Cochet-Bonnet aesthesiometer, 703 
corneal sensitivity is assessed observing the patient’s subjective reaction to different lengths of a 704 
protruding nylon filament applied to the cornea which is extended from 60mm to 5mm with a 705 
corresponding change in force from 11 to 200 grams/mm. After touching the cornea in the 706 
quadrant to be tested, pressure is applied on the filament to induce a gentle bend. At this point 707 
the patient should appreciate the touch of the filament tip. The length is reduced in 5mm steps 708 
until the patient appreciates the touch. The longer the length at which the patient feels the touch 709 
36 
 
of the filament, the higher the corneal sensitivity. Measurements are performed in each quadrant 710 
of the cornea and data recorded accordingly (Golebiowski et al., 2011). 711 
The BNGA works by stimulating the cornea with a calibrated gas emission from an 712 
injector kept close to the cornea and subsequent blink response. The BNGA is mounted on a slit-713 
lamp (similar to an applanation tonometer) with the gas injection tip kept perpendicular to the 714 
cornea, the subject is instructed to look at a fixation target at 3 m, and the injection tip is kept 715 
5mm away from the surface, (the distance is measured with a transparent ruler). Subjects are 716 
instructed to close and open their eyes just before triggering the stimulus. By varying the flow, 717 
temperature and composition of gas (CO2 concentration) this device can assess different 718 
components of corneal sensation i.e. mechanical, chemical and thermal sensitivity.  The 719 
technique has been found to be safe and reproducible and its ‘non-contact’ nature makes it safer 720 
than contact methods (Belmonte et al., 1999; Teson et al., 2012). 721 
9.5.2  Imaging Corneal Nerves 722 
In vivo confocal microscopy (IVCM) (Fig. 110) allows qualitative and quantitative 723 
assessment of corneal nerves in health and disease. Nerve density, tortuosity, angulation, 724 
thickness and reflectivity are assessed using image analysis programmes. IVCM has been used to 725 
detect corneal nerves changes in a variety of conditions such as keratconus, bullous keratopathy, 726 
diabetic neuropathy and herpes simplex keratitis (Al-Aqaba et al., 2011a; Al-Aqaba et al., 2011b; 727 
Cottrell et al., 2014; Messmer et al., 2010). In diabetic neuropathy, analysis of corneal nerve 728 
density and morphology has demonstrated a correlation between reduction in fibre 729 
density/branching and severity of somatic neuropathy. The method is sensitive enough to detect 730 
significant structural abnormality in the corneal nerves of patients deemed to have mild diabetic 731 
neuropathy by conventional tests and can help detect onset of diabetic peripheral neuropathy 732 
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prior to clinical manifestation. In pre-ganglionic (trigeminal ganglion) lesions and partial 733 
ganglion lesions, corneal sensitivity can be absent or diminished but IVCM demonstrates a 734 
normal sub-basal plexus with mild NK. In post-ganglionic or complete ganglionic lesions the 735 
sub-basal plexus is attenuated or lost, corneal sensations are reduced and the risk of developing 736 
moderate to severe NK is high (Dhillon et al., 2016). Accurate imaging and quantitative analysis 737 
of images of sub-basal and stromal nerves can be affected in corneas presenting with severe NK 738 
due to the possible influence of concurrent stromal oedema, infiltration, melting or scarring.  739 
9.5.3 Anterior Segment Optical Coherence Tomography (ASOCT) 740 
Fourier domain ASOCT can demonstrate corneal nerve abnormalities (radial 741 
keratoneuritis) such as during active acanthamoeba keratitis (Yamazaki et al., 2014) and can be 742 
used to assess treatment response. However, current instrumentation has insufficient resolution 743 
to resolve corneal nerve architecture changes where the sole abnormality is loss of corneal 744 
sensation. ASOCT comes in handy to assess corneal thickness changes as may occur during 745 
moderate to severe NK; providing both morphometric and qualitative data. ASOCT can be used 746 
for measuring the depth of stromal ulcerations and stromal thickness changes occurring over 747 
time in NK (Fig. 121), facilitating the diagnosis of cases at risk of perforation and improving the 748 
follow-up analysis after surgical tectonic grafts of amnion or corneal transplantation (Nubile et 749 
al., 2011). 750 
9.6 Differential diagnosis 751 
 Several chronic diseases can lead to NK and others can mimic NK, the key distinction 752 
being the alteration/absence of corneal sensation. The terms primary and secondary NK have 753 
been used as descriptors but there is are no differences clinically in the corneal manifestations 754 
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once the process is driven by loss of trophic and sensory function. Systemic causes such as 755 
trigeminal nerve damage from tumour, trauma or surgery, or neuropathy associated with diabetes 756 
and multiple sclerosis can be considered as examples of primary NK whereas damage to the 757 
corneal innervation from direct insult to the cornea such as following viral infections, corneal 758 
transplantation or refractive surgery, can be considered as examples of secondary NK. Central 759 
and peripheral NK are term that also reflect the site of lesions that can cause NK, analogous to 760 
primary and seconday NK. In central NK corneal and conjunctival sensations are likely to be 761 
affected compared to peripheral NK where only corneal sensations are likely to be 762 
predominantly affected. In the majority of cases NK is a unilateral disease. Where the cause is 763 
diabetic neuropathy or multiple sclerosis it can be bilateral. 764 
 Dry eye disease, contact lens related disorders, blepharo-keratoconjunctivitis, limbal stem 765 
cell deficiency, exposure keratopathy, radiation keratopathy, topical drug and preservative 766 
toxicity and chronic eye rubbing are important conditions that can have overlapping features 767 
with NK and may remain as independent entities until corneal sensitivity is affected.  768 
 769 
10. Management 770 
Left untreated, NK can evolve into a devastating condition culminating in anatomical loss 771 
of the eye. Short of this, loss of vision is common even with treatment. Management of NK can 772 
be divided into medical management, non-surgical intervention and surgical management. These 773 
can be considered in a step-ladder approach according to NK stage/severity but are not exclusive 774 
as often a combination of options may need to be considered. The objective of treatment is to 775 
arrest progression and reverse NK changes that have occurred at the time of presentation. In mild 776 
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NK (stage 1), the objective is to prevent epithelial breakdown and encourage healing of epithelial 777 
erosions. In moderate NK (stage 2), the objective is to encourage re-epithelialisation of the 778 
denuded stroma and prevent progression to stromal melting. In severe NK (stage 3), the objective 779 
is  to prevent perforation and promote healing. Throughout the course of NK maintenance of 780 
comfort and optimizing vision are also therapeutic considerations. 781 
10.1 Medical Management of NK 782 
Considerations for the medical management depend upon the severity / stage of NK and 783 
pathology of the underlying disease process. Therapeutic approaches are broadly divided into 784 
strategic areas that encompass categories of treating the underlying disease process, treating any 785 
concurrent infections, preventing disease progression, promoting epithelialisation, providing tear 786 
replacement, reducing inflammation, preventing stromal tissue loss or perforation and avoiding 787 
complications. The current step-ladder of interventions for NK according to severity is 788 
summarised in table 3. 789 
10.1.1 Treatment of concurrent inflammation  790 
10.1.1.1 Infection 791 
Culture or PCR of forniceal swabs to identify common and unusual pathogens that may 792 
be present in abundance on a compromised ocular surface driving inflammation through 793 
activation of innate immune responses, is essential (Kugadas and Gadjeva, 2016). Identified 794 
organisms (bacteria, fungi, and viruses) should be treated. However, when infection is suspected 795 
but cultures are negative, empirical treatment with Azithromycin 1g orally for 3 days is 796 
advised.Due to false negatives, empirical treatment with Azithromycin 1g orally for 3 days is 797 
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advised. For persistent epithelial defects, secondary infection delaying healing should be 798 
excluded and the eye treated with broad spectrum topical antibiotics. Wherever possible, toxic 799 
aminoglycosides such as gentamicin should be avoided unless sensitivities dictate otherwise. 800 
Topically administered quinolones can also be toxic to the ocular surface (Ayaki et al., 2012; 801 
Mencucci et al., 2011; Walter and Tyler, 2001). Drug toxicity should be suspected when initial 802 
clinical improvement changes to clinical worsening and increased inflammation. The ‘up-down’ 803 
test, where in the upper bulbar conjunctiva appear white compared to the lower injected bulbar 804 
and fornicial conjunctiva, is a useful early indicator of drug toxicity. (Dua et al., 2012).  805 
10.1.1.2 Minimise ocular irritants and conservative treatment 806 
Awareness of iatrogenic causes of ocular toxicity is critical (Dart, 2003). All preserved 807 
therapy should, wherever possible, be discontinued. Detection of corneal deposits such as 808 
fluoroquinolone crystals (ciprofloxacin, ofloxacin) (Claerhout et al., 2003; Mitra et al., 2007), or 809 
hydroxyapatite formation due to a combined effect of hyaluronates and phosphates (Bernauer et 810 
al., 2006a), or calcific deposits after the use of steroid-phosphate (Schlotzer-Schrehardt et al., 811 
1999), retinoic acid (Avisar et al., 1988), or lubricant phosphates (Bernauer et al., 2006b) should 812 
lead to clinical approaches that minimise potentially damaging drug/chemical precipitation 813 
reactions on the ocular surface.  814 
Patients should also be advised to refrain from using irritating peri-ocular cosmetics, 815 
increase humidity by wearing protective moisture chamber wrap-around glasses or goggles, and 816 
consider increasing dietary omega-3 fatty acids (Eicosapentaenoic acid (EPA)) or linoleic acid 817 
and gamma-linolenic acid (Flaxseed oil). Fish oils have been shown to provide modest benefit to 818 
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the ocular surface by inhibiting pro-inflammatory mediators (Prostaglandin E2, Leukotriene B4,  819 
IL-1 and TNFα) (Kangari et al., 2013). 820 
10.1.1.3 Reduce Inflammation 821 
The use of non-preserved topical medications is essential to minimise ocular surface 822 
inflammation. Meibomian gland dysfunction should be treated with warm compresses possibly 823 
with the aid of proprietary eye-lid warming devices, lid massage and hygiene with diluted 824 
sodium bicarbonate or commercially available lid hygiene wipes. The use of matrix 825 
metalloproteinases inhibitors in the form of low dose tetracyclines or macrolides is advised. The 826 
mainstay is with the use of topical non-preserved glucocorticoids such as prednisolone or 827 
dexamethasone (Geerling et al., 2011). Delayed wound healing related to steroid medication, 828 
pharmacokinetically only occurs at higher doses or with longer duration of treatment. 829 
Nevertheless, inhibition of stromal healing, may increase the risk of corneal stromal melting and 830 
perforation, thus their use should be considered with caution. Vigilant screening for steroid-831 
related raised intraocular pressure and optic neuropathy is required. Soft steroids such as 832 
medroxyprogesterone 1%-2% and androgens (if available) may ameliorate this risk. Topical non-833 
steroid anti-inflammatory drugs (NSAID) treatment does not improve the healing process. 834 
NSAIDs are generally avoided due to their epithelial toxicity and the risk of corneal ulceration 835 
(Guidera et al., 2001; Gaynes and Fiscella, 2002; Lee and Himmel, 2006; Feiz et al., 2009).. 836 
Topical ciclosporin is only licensed for use in primary or secondary dry eye disease. 837 
Ciclosporin 0.1% (Ikervis® SDU) is licensed for severe keratitis of dry eye disease not 838 
responding to ocular lubricants. In the US and Far East, Ciclosporin 0.05% (Restasis®) may be a 839 
useful alternative. PADciclo 0.06% is currently undergoing clinical trials. The veterinary 840 
preparation, Ciclosporin 0.2%, (unlicensed, Optimmune®) may also be considered if an ointment 841 
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with lubricating properties is required. Although tacrolimus 0.03% to 0.1% has been shown to be 842 
effective in combating ocular surface inflammation, its use in the context of NK has not been 843 
studied (Fukushima et al., 2014; Kiiski et al., 2014). 844 
10.1.2 Tear substitution 845 
Ocular lubricants reduce biomechanical shear forces and dilute pro-inflammatory 846 
mediators in the tear film thereby promoting epithelialisation. They are generally classified 847 
according to viscosity ranging from low to high and are summarised in table 4. Due to the 848 
toxicity associated with preservatives (Baudouin et al., 2010; Geerling et al., 2001; Gomes et al., 849 
2017), unpreserved lubricants are prescribed, many of which can be bought over the counter by 850 
the patient. Carmellose agents are cytoprotective (Garrett et al., 2007), and hyaluronate ligation 851 
to CD44 expressed on injured ocular surface epithelial cells, deliver anti-inflammatory properties 852 
in addition to facilitating epithelial wound healing (Gomes et al., 2004). Other compounds such 853 
as guar gums, liposomes and soybean/mineral oil combinations, help stabilise the phospholipid 854 
layer whilst other agents confer osmoprotection (glycerine, L-Carnitine, erythritol, threalose). In 855 
patients with filamentary keratitis, mucolytics (acetylcysteine 5-10%) may be beneficial. Recent 856 
clinical trials indicate promising results for the use of diquafosol 3% (a P2Y2 receptor activator 857 
that improves mucociliary clearance and mucin production) and rebamipide 2% (that stimulates 858 
transmembrane mucin MUC16 biosynthesis) in multifactorial dry eye disease, although the exact 859 
benefit for NK is yet to be determined. Alternative non-preserved lubricants such as saline 0.9% 860 
(that has no excipients) or balance salt solution should be considered in resistant cases. 861 
Nutritional tear substitutes (serum eye drops) are considered when all treatment options have 862 
been exhausted. Unlike other pharmaceutical tear supplements, nutritional substitutes contain 863 
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substances that are also present in natural lacrimal tears and support ocular surface epithelial 864 
growth and regeneration. These include growth factors (epidermal growth factor and 865 
transforming growth factor beta), Vitamins (A, C),  glucose, natural antimicrobials (surface IgA, 866 
defensins, lysozyme), and proteins involved in wound healing (fibronectin) (Rauz and Saw, 867 
2010). Most commonly used are autologous serum eye drops (Azari and Rapuano, 2015; 868 
Semeraro et al., 2014; Turkoglu et al., 2014), but there is a risk of instilling circulating antibodies 869 
or pro-inflammatory mediators in patients with systemic diseases e.g. Multiple sclerosis, mucous 870 
membrane pemphigoid that have the potential to exacerbate disease processes in the eye. 871 
Allogeneic serum eye drops (available in the UK, Germany, New Zealand) are obtained from 872 
young healthy male donors and avoid cyclical oestrogen hormone variances that may have pro-873 
inflammatory effects on the surface of the eye. Human umbilical cord serum has been shown to 874 
contain higher levels of growth factors, including nerve growth factor, and other constituents 875 
similar to those in tears, and has been used to treat a variety of ocular surface conditions 876 
including NK (Yoon et al., 2005; Yoon et al., 2007). The response to cord blood serum appears 877 
to be related to the severity of NK with mild to moderate (stages 1 and 2) lesions responding 878 
quicker than severe (stage 3) defects. (Erdem et al., 2014).  Human cord blood serum eye drops 879 
has greater concentrations of nerve growth factor and other mediators but sHowever, small 880 
volumes obtained from the placenta, limits general use. Platelet-rich plasma (PRP) is abundant in 881 
growth factors that promotes ocular surface regeneration (Hartwig et al., 2004; Hartwig et al., 882 
2005). Despite the differences in methods used to prepare this product for clinical use, studies 883 
indicate that PRP gives better results than autologous serum and can lead to healing of persistent 884 
epithelial defects where autologous serum drops have failed. They also have a good safety 885 
profile (Kim et al., 2012; López-Plandolit et al., 2010; Soni and Jeng, 2016). Its content of 886 
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biologically active proteins, growth factors, and biomaterial scaffolds make PRP a therapeutic 887 
agent promoting ocular surface wound healing and regeneration (Anitua et al., 2016). PRP has 888 
also demonstrated efficacy, as a monotherapy, in the management of post laser refractive surgery 889 
‘ocular surface syndrome’ (Alio et al., 2017).  890 
 891 
 892 
 893 
 894 
10.1.3 Prevent stromal tissue loss 895 
Stromal degradation occurs after the release of proteolytic enzymes from recruited inflammatory 896 
cells, activation of clotting and kinin cascades that induce further inflammation and stromal loss.  897 
Matrix metalloproteinases inhibitors (oral tetracyclines and topical acetylcysteine) restrict 898 
neutrophil collagenase and epithelial gelatinase gene expression, suppress alpha-1 antitrypsin 899 
degradation and scavenge reactive oxygen species (Ogut et al., 2016; Hahn et al., 2016; Abdul-900 
Hussien et al., 2009; Sekundo et al., 2002). Ascorbate applied topically or given systemically, 901 
provides cofactors for collagen synthesis as well as scavenging for oxygen free radicals.  Topical 902 
citrate, if available, is a calcium chelator inhibiting neutrophil degranulation and release of 903 
proteolytic enzymes as well as inhibiting collagenases (Parker et al., 1985). 904 
 905 
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10.1.4. Biological medical products 906 
Drugs given systemically targeting mediators that fuel inflammation or delay wound 907 
healing have gathered momentum over the past two decades, although very few biologics have 908 
been licensed for ocular use.  Topically administered biologics or biosimilars provide an 909 
attractive area for drug development. Murine NGF (Bonini et al., 2000; Lambiase et al., 1998), 910 
Substance P and Insulin-like growth factor (Yamada et al., 2008) were the first mediators to 911 
show encouraging results (Fig. 132). A number of novel treatment modalities have emerged 912 
through clinical trials and are available for clinical use. These include recombinant human NGF 913 
(rhNGF,  cenegermin (betaNGF) (European Medicines Agency, 2017), lifitegrast 5% 914 
(lymphocyte function-associated antigen-1 (LFA-1) antagonist) (Perez et al., 2016), 915 
ReGeneraTing Agent [RGTA] – matrix therapy agent, Cacicol20, Thymosin beta 4, Conenzyme 916 
Q10, Substance P, Netrin-1 (class of proteins involved in axon guidance and cell migration) and 917 
Nexagon® (an antisense oligonucleotide that downregulates expression of the gap junction 918 
protein Cx43, which is increased in pathological conditions with persistent epithelial defects) 919 
(Guerra et al., 2017). Many of these agents promote healing in a generic way by combating 920 
inflammation (lifitegrast) or rejuvenating the stroma by providing binding sites for growth 921 
factors to promote healing (RGTA). NGF specifically targets the deficit in NK by replacing the 922 
nerve growth factor and promoting epithelial healing and nerve health.  923 
Cenegermin is a recombinant form of human nerve growth factor (rhNGF) produced in 924 
Escherichia coli as a pro-peptide, which is later cleaved to mature NGF. The molecule is 925 
identical to human NGF (European Medicines Agency, 2017).  The European Medicines Agency 926 
recently (July 2017) granted Cenegermin 20 μg/ml (Oxervate®) full marketing authorization for 927 
the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) NK in adult 928 
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patients by, making it the first approved medical treatment for this specific indication. The 929 
efficacy and safety of cenegermin were evaluated in two independent, multicentre, randomised, 930 
double-masked, vehicle-controlled clinical studies (NGF0212 and NGF0214) in patients with 931 
moderate or severe NK refractory to non-surgical treatments. In both studies patients received 932 
cenegermin or vehicle 6 times daily in the affected eye(s) for 8 weeks,  and were followed-up.  933 
Study NGF0212 (NCT01756456) conducted in Europe, enrolled a total of 174 patients (mean 934 
age 61±16 years); 156 patients were assessed independently for efficacy, comparing two 935 
different dosages of the medicinal product with 20 and 10 µg/ml cenegermin to vehicle (52 936 
patients per arm) (Mantelli et al., 2017; Sinigaglia and NGF Study Group, 2014). Study 937 
NGF0214 (NCT02227147), run in US, enrolled 48 patients (mean age 65±14 years) treated with 938 
cenegermin 20 µg/ml or vehicle (24 patients per arm) (Chao et al., 2017). A summary of the 939 
results of the two studies in relation to cComplete corneal healing of the persistent epithelial 940 
defect or corneal ulcer (the key efficacy primary endpoint, defined as the greatest diameter of 941 
corneal fluorescein staining <0.5 mm) after 4 and 8 weeks of treatment for patients who received 942 
cenegermin 20 µg/ml or vehicle was compared. , is given in table 5. There was a statistically 943 
significant improvement to complete healing of the cornea at 4 and 8 weeks of treatment (58.0% 944 
and 74.0% respectively) compared to vehicle (19.6% and 43.1% respectively) (p <0.001 and 945 
<0.002) in study NGF 0212. In study NGF 0214 the difference was statistically significant at 8 946 
weeks of treatment (69.6% with cenegermin and 29.2% with vehicle, p<0.006). 947 
 948 
10.2 Non-surgical interventions 949 
10.2.1 Eyelid closure      950 
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Tarsorrhaphy, the suturing of the eyelids to narrow the interpalpebral fissure is a 951 
cornerstone of NK management. Non-surgical techniques that can be used as an alternative to 952 
tarsorrhaphy include eyelid closure with tape, pressure patching, pad and bandage and botulinum 953 
toxin injection induced ptosis. In principle these have the same objective of covering the cornea, 954 
protection against the environment and effects of lid blinks. Contact lenses may also serve a 955 
similar purpose. 956 
Placing an adhesive tape (transpore) across the closed eyelids is a simple intervention to 957 
keep the lids closed. This is routinely employed by anesthetists to prevent exposure of the cornea 958 
during surgery under general anesthesia. When used in the context of non-healing epithelial 959 
defects of the cornea Tthe limitation of taping is that if repeated removal and (re) application is 960 
required to instill eye drops or examine the eye, the delicate skin of the lids can excoriate and be 961 
bruised. The ‘Apache patch’ and invention of Mr B Donaldson of Aberdeen, Scotland, is a clever 962 
eye patch device which has two components, a ‘T’ shaped part for the upper lid with adhesive 963 
backing to the horizontal limb and a small rectangular part, with adhesive backing, for the lower 964 
lid. The lower end of the vertical limb can be affixed to the part on the lower lid with Velcro. 965 
This allows the Velcro components canto be separated and reattached without removing the 966 
device from  the lids. The Frost suture (can be considered a surgical intervention), which 967 
involves the placement of suture (4 ‘0 silk) horizontally through the skin of the upper (or lower) 968 
lid close to the lash line, serves a similar purpose. The suture is cut to desired length and the two 969 
ends tied. The suture can then be used as a ‘handle’ to pull the upper lid down (or the lower lid 970 
up) and close the eye and keep it closed by fixing the suture to the cheek (or forehead) with 971 
adhesive plaster. Use of an eye pad with tape or bandage provides complete closure with some 972 
pressure. Usually two pads are used, one folded in half and applied on the closed lids to fill the 973 
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space of the anterior orbit, and the other placed on this and attached with a couple of strips of 974 
tape running from the forehead to cheek or held in place with an eye bandage. These are useful 975 
when closure for the whole day is required and not when the eye has to be opened frequently 976 
during the day. The drawback of needing to undo the patch or eyelid tape every time an eye drop 977 
is due has to be administered, makes them impractical. Importantly, care has to be taken to 978 
ensure that the lids do not open under the patch as this would allow the patch to rub against the 979 
cornea and aggravate the condition. 980 
Botulinum toxin induced ptosis is an exception to the above. It provides a safe, rapid and 981 
effective means of closing the eye whilst still allowing for easy access to examine or instill 982 
eyedrops (Fig. 143). An injection of botulinum toxin is administered at the upper border of the 983 
superior tarsal plate or over the belly of the levator palperae superioris muscle and induces 984 
paralysis thereof causing the upper lid to droop and completely cover the cornea. The effect 985 
typically lasts 6 to 12 weeks. The number of units, dilution and volume to be injected varies 986 
according to form of botulinum toxin used. Another consideration is that the effect of the toxin is 987 
not immediate and can take several hours or a couple of days. Hence repeat injections should be 988 
avoided in the same week. In cases where only partial closure occurs, lagophthalmos may result 989 
in exposure and compound the problem and a further injection of botulinum toxin may be 990 
required (Kirkness et al., 1988; Schilimow and Wiechens, 2016). 991 
10.2.2 Therapeutic Contact Lenses 992 
Therapeutic contact lenses are fitted to maintain the integrity of the ocular surface tissues 993 
where improvement of vision is secondary benefit.  Commonly used biomaterials are silicone 994 
hydrogels and rigid gas permeable,  that are fitted as corneal, limbal, semi-scleral or scleral 995 
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lenses. Rigid gas permeable scleral contact lenses are vaulted away from the cornea and 996 
supported by the anterior sclera. The design creates a reservoir between the lens and cornea that 997 
captures therapeutic substances and increases retention time of therapeutic agents and lubricants 998 
on the ocular surface. One such device is the prosthetic replacement of the ocular surface 999 
ecosystem (PROSE) device. The use of contact lenses in the context of NK must be accompanied 1000 
by extreme vigilance. The reduction of sensation reduces ‘alarm’ signals for infection. If used, 1001 
prophylactic use of topical non-preserved antibiotics is advised (Baenninger et al., 2014). 1002 
Innovative devices using a combination of amniotic membrane and a contact lens are in 1003 
vogue. The OmniLenz® and Prokera™ (see later) are examples.  OmniLenz® consists of a soft 1004 
contact lens lined with a circular disc of vacuum dried amniotic membrane and is applied 1005 
directly on the corneal surface. The amniotic membrane rapidly hydrates and provides a soft 1006 
biological cover to the defect. It is suggested that the release of molecules from the amniotic 1007 
membrane favour healing. Evidence from clinical trials is lacking though anecdotal experience 1008 
with single cases has shown a beneficial effect. 1009 
10.2.3 Punctal Occlusion 1010 
The tear film contains many factors that aid in corneal epithelial and stromal healing. 1011 
These include growth factors, such as EGF, TGF, TGF-β, bFGF, HGF, and vitamins A and C, 1012 
and fibronectin. Increasing the amount of tears in the eye can aid in the healing of epithelial 1013 
defects and nonhealing ulcers. In addition, tears lubricate the surface of the eye, remove disease-1014 
causing pathogens, and protect healing epithelium. Low volume of tears can be compensated for 1015 
either by adding artificial tears or decreasing tear egress from the palpebral fissure. Tear 1016 
substitutes do not contain the growth factors and vitamins present in natural tears. Punctal 1017 
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occlusion increases the retention of natural tears enhancing the healing process (Cohen, 1999; 1018 
Guzey et al., 2001). Punctal occlusion can be performed by various methods (Baxter and 1019 
Laibson, 2004). Punctal plugs – these can be temporary or short acting collagen plugs,  or 1020 
permanent punctal or canalicular plugs. The punctae can be also be permanently occluded with 1021 
thermal cautery. Other methods of  occluding the puncta, include argon laser, suturing of the 1022 
punctum, or canalicular ligation (DeMartelaere et al., 2006; Hutnik and Probst, 1998; Liu and 1023 
Sadhan, 2002). 1024 
Punctal plugs can be associated with complications, such as pyogenic granulomas, 1025 
bacterial colonization, extrusion, and local irritation (Kim et al., 2005; Sugita et al., 2001; Tai et 1026 
al., 2002). Timing is critical as early insertion during active inflammation may lead to the 1027 
accumulation and stagnation of tears loaded with pro-inflammatory cytokines and pro-1028 
inflammatory mediators gene expression on the ocular surface (Tong et al., 2016).  1029 
10.3 Surgical intervention 1030 
Surgery is often required in advanced disease refractory to medical management, mainly 1031 
in moderate and severe NK (stages 2 and 3). Medical and surgical options are not mutually 1032 
exclusive and are often combined. 1033 
10.3.1 Permanent punctual occlusion  1034 
Where temporary punctual occlusion has been successful in improving the tear reservoir, 1035 
epiphora has not occurred and there is no prospect of a return of normal lacrimation then 1036 
permanent punctual occlusion may be considered. This is particularly beneficial in patient likely 1037 
to require lifelong punctual occlusion in whom punctal plugs can give rise complications stated 1038 
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above. Cauterisation of the vertical part of the canaliculus and punctum with heat is the standard 1039 
method to achieve this. 1040 
10.3.2 Tarsorrhaphy 1041 
Tarsorrhaphy provides a more definitive closure of the eyelids by approximating the 1042 
upper and lower lids. This is considered as the gold standard in NK treatment in several centres 1043 
(Fig. 154). Closure of the lids protects the cornea from the environment, prevents epithelial 1044 
damage by the friction caused by eyelid movement especially when the lid margins are irregular 1045 
and keratinized (Cosar et al., 2001), conserves tear fluid and provides a reservoir of tears to keep 1046 
the eye constantly moist and theoretically, the approximation of the vascular palpebral 1047 
conjunctiva to the corneal surface affords additional unknown benefit. Tarsorrhaphy can be 1048 
temporary or permanent, depending largely on the natural history of the underlying etiological 1049 
condition  (Allen and Malinovsky, 2003), partial (lateral, medial, central) or complete, depending 1050 
on the severity of NK. 1051 
Of the various techniques of performing a tarsorrhaphy, the most common is suturing the 1052 
lids to each other over bolsters. This tarsorrhaphy reverses when the suture is removed and often 1053 
the suture loosens after a few days or weeks. If the lid margins are denuded prior to suturing, the 1054 
tarsorrhaphy is permanent, and if they are not, it is temporary. The advantage of (lateral) 1055 
tarsorrhaphy over corneal patching is that the eye can be examined, the patient has vision, and 1056 
the risk of infectious keratitis is reduced (Ali and Insler, 1986; Cosar et al., 2001; Panda et al., 1057 
1999). Tarsorrhaphy should be considered in all cases of persistent epithelial defects that fail to 1058 
respond to medical treatment and/or non-surgical interventions (Tuli et al., 2007). If healing 1059 
occurs, the tarsorrhaphy opening may be enlarged after a few weeks, but opening the 1060 
tarsorrhaphy prematurely may results in a recurrence of corneal epithelial breakdown, especially 1061 
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if total corneal anaesthesia persists.  1062 
10.3.3 Debridement 1063 
At times, the leading edges of the healing epithelium may thicken and become rolled or 1064 
heaped, impeding migration across the defect. In such cases, the epithelium at the edges of the 1065 
defect may be removed, effectively enlarging the defect. This triggers the healing response in the 1066 
surrounding epithelium promoting migration to close the defect (Katzman and Jeng, 2014). 1067 
10.3.4 Amniotic Membrane Transplantation (AMT) 1068 
The amniotic membrane AM) is a versatile tissue that has caught the imagination of 1069 
ophthalmologists and has been used for a wide variety of indications across several ophthalmic 1070 
subspecialities. Its efficacy has been adequately demonstrated (Azuara-Blanco et al., 1999; Dua 1071 
et al., 2004; Gomes et al., 2005), but equally it is at times used “as something to do rather than 1072 
something that does” (hsd) (Clare et al., 2012; Joseph et al., 2001; Rahman et al., 2009). AM can 1073 
be used as a graft (inlay) or a patch (onlay) (Bonini et al., 2003). When the AM is applied such 1074 
that epithelium migrates on the membrane and the amnion becomes incorporated in the cornea, it 1075 
is termed a ‘graft’ (Fig. 165). Conversely if the healing epithelium migrates under the AM and 1076 
the amnion later falls off or is removed, it is termed a ‘patch’.  At times two membranes can be 1077 
used one as a graft and the other as a patch over the graft. AMT can be combined with 1078 
tarsorrhaphy but individually they have shown efficacy in the treatment of refractory 1079 
neurotrophic corneal ulcers (Khokhar et al., 2005). Multiple pieces of AM cut to fit the shape of 1080 
the defect can be stacked and finally covered by a graft or patch (Prabhasawat et al., 2001). The 1081 
amnion allows keratocytes to migrate in the AM stroma and lay down collagen/scar tissue, which 1082 
helps build the tissue at the site of melt. Multiple layers of amniotic membrane can integrate into 1083 
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the corneal stroma with resulting increase in corneal thickness; however keratocyte-mediated 1084 
wound healing and remodeling of the incorporated amniotic tissue induces progressive 1085 
contraction and changes in tissue transparency (Nubile et al., 2011). In the context of NK it has 1086 
proven efficacy and is usually used in severe NK (stage 3) but has been used in mild and 1087 
moderate NK (stages 1 and 2). (Gris et al., 1999).  1088 
Fresh, cryopreserved (Amniograft), freeze dried (Ambio dry) and vacuum dried 1089 
(Omnigen) amnion are available and all have demonstrated efficacy to a lesser or greater extent,  1090 
with the latter two offering advantages of ease of storage and transportation at room temperature.  1091 
All human derived tissue carries a serious risk of transmission of infectious disease. Though 1092 
‘fresh’ amnion is still used in some parts of the world, the practice does not allow sufficient time 1093 
for a thorough testing for microbial contamination. Where serological testing is performed, the 1094 
donor is tested at the time of donation and the tissue quarantined for 6 months, when a repeat test 1095 
is performed. The material is released for clinical use only when both tests are negative. With 1096 
PCR testing on tissue samples, it is possible to release tissue within a week, when theoretically it 1097 
would be classed as ‘fresh’. The membranes can be applied to the defect with tissue glue (fibrin 1098 
glue, Tisseel®) or sutures. Lyophilized AM has been shown to have lower concentrations of 1099 
proteins/growth factors (Rodriguez-Ares et al., 2009). AM has many features that make it 1100 
extremely useful for the prevention and treatment of corneal ulceration (Tseng et al., 2004). Its 1101 
basement membrane is composed of collagen types IV and VII, laminin 1 and 5 and fibronectin 1102 
(Cooper et al., 2005). The laminin and fibronectin assist in epithelial cell adhesion and are 1103 
therefore useful in treatment of PEDs (Cameron et al., 1988; Nakagawa et al., 1990). The stroma 1104 
also contains multiple growth factors (EGF, TGF-α, KGF, HGF, bFGF, TGF-β1, -β2), anti-1105 
angiogenic factors (thrombospondin-1 and collagen VIII), TIMPs (1,2,3 and 4) and anti-1106 
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inflammatory factors (IL-1 receptor inhibitor and IL-10) that may help in the resolution of ulcers 1107 
and decrease scarring (Koizumi et al., 2000). The major use of AMT in corneal pathology is in 1108 
the management of neurotrophic ulcers (severe NK) and PEDs. Kruse et al. evaluated multilayer 1109 
AMT in neurotrophic ulcers that had failed after at least 4 weeks of conventional therapy with 1110 
lubrication, patching, or bandage contact lenses. They found that all the ulcers resolved at 4-5 1111 
weeks following AMT, but the surface layer of AMT disappeared faster than the ulcer healed, 1112 
and multiple layers were necessary to achieve resolution of the ulcer (Kruse et al., 1999). Chen et 1113 
al. performed a similar study on longstanding neurotrophic ulcers of various etiologies that had 1114 
failed conventional therapy (Chen et al., 2000). They found that 76% of the eyes had rapid 1115 
epithelial healing within 16 days. However, more than half of their patients also needed 1116 
adjunctive therapy with tarsorrhaphy, bandage contact lens, or bandage amniotic membrane, 1117 
reiterating that single layer AMT may not be sufficient for severe neurotrophic ulcers.   1118 
Prokera™, which consists of an amniotic membrane clipped into a dual PMMA ring set, 1119 
has been used for the treatment of chronic ulcers. The advantage of this device is that it does not 1120 
need sutures for placement and can be easily slipped into the eye like a large scleral contact lens 1121 
(Suri et al., 2013). Other commercially available are Amnion (Bio-Tissue, Inc., Miami, FL), 1122 
fresh frozen, and Ambiodry2 (IOP Ophthalmics, Costa Mesa, CA), freeze-dried. A suspension of 1123 
homogenized amniotic membrane in BSS has been used topically in patients with ulcers 1124 
refractory to conventional therapy. Healing of all ulcers occurred by 28 days following 1125 
institution of therapy (Bonci et al., 2005). 1126 
10.3.5 Tissue adhesives 1127 
Tissue adhesives have been used for the closure of corneal defects and perforations for 1128 
many years (Bloomfield et al., 1963; Refojo et al., 1968). In the presence of a small perforation 1129 
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(less than 3mm) the application of tissue adhesive on the lesion, followed by the application of a 1130 
soft bandage contact lens or AMT is the procedure of choice. Larger defects require a 1131 
conjunctival flap or lamellar keratoplasty (Mantelli et al., 2015). Two basic types of adhesives 1132 
are used in ophthalmology, synthetic (cyanoacrylate) and biologic (fibrin glue) (Bhatia, 2006). 1133 
Cyanoacrylate polymerizes rapidly in the presence of water (tissue fluid) and also releases 1134 
formaldehyde during polymerisation. Formaldehyde contributes to its antibacterial activity 1135 
against most gram-positive organisms (de Almeida Manzano et al., 2006; Diaz-Valle et al., 1136 
2003). It forms a rigid, impermeable plaque on the surface of the eye, which needs to be covered 1137 
with a bandage contact lens to offer protection and avoid pain and trauma to the upper lid. The 1138 
contact lens also prevents the glue being dislodged by lid movement. It remains in the eye long-1139 
term, as it is not biodegradable. Multiple perforations or a single perforation that continues to 1140 
leak from the edge of the first patch of glue application, requires one or more overlapping further 1141 
applications (Fig. 176). When there is a perforation with iris prolapse, the double drape 1142 
technique can be used. The prolapsed iris is covered with a circular disc of plastic drape without 1143 
glue and this in turn is covered with a larger disc of plastic drape with cyanoacrylate glue. The 1144 
second disc adheres to the corneal tissue around the first disc, which prevents the glue from 1145 
directly adhering to the iris (Gandhewar et al., 2013). The epithelium usually grows under the 1146 
glue and healing of the defect usually dislodges the glue. 1147 
  Fibrin glue polymerizes relatively slowly and is therefore less effective in frank 1148 
perforations with a brisk leak. Fibrin is also rapidly degraded, but the addition of aprotinin 1149 
(antifibrinolytic agent) delays lysis for up to 10-14 days. Placement of a bandage contact lens 1150 
after fibrin glue application also helps to retard degradation possibly by preventing access of 1151 
polymorphonuclear cells and their proteases. The fibrin scaffold allows migration of 1152 
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keratocytes/fibroblasts and myofibroblasts, which in turn lay down collagen and help close the 1153 
defect. Fibrin glue carries a theoretical risk of disease transmission as it is derived from pooled 1154 
plasma. The advantage of fibrin glue is the higher comfort level and the absence of toxic 1155 
metabolites (Sharma et al., 2003). 1156 
10.3.6 Conjunctival Flap 1157 
A conjunctival flap may be indicated to prevent progression of the epithelial defect to 1158 
perforation (Pushker et al., 2001). Total conjunctival flaps are more useful in patients with severe 1159 
stromal damage and poor visual prognosis. Partial or bridge flaps may be used for small or 1160 
peripheral ulcers. Conjunctival flaps have some disadvantages that include corneal perforation 1161 
under the flap, flap retraction, poor reversibility and the need for an operating room. Despite the 1162 
disadvantages, conjunctival flaps can be helpful because they halt the inflammatory process, and 1163 
eliminate need for frequent instillation of medication. 1164 
The procedure of using a flap of bulbar conjunctiva to cover nonhealing corneal 1165 
ulceration was first described by Trygve Gundersen in 1958 (Gundersen, 1958). Gundersen’s 1166 
flaps were frequently used for this purpose, but they fell into disfavor because they were difficult 1167 
to fashion, especially in patients who had undergone multiple ocular surgeries, and they 1168 
sometimes retracted. Other modalities for treating these conditions, such as disposable 1169 
therapeutic contact lenses and AMT, were also much easier to use. However, in selected cases, 1170 
conjunctival flaps may be superior, as they can replace an unhealthy stromal bed with healthy 1171 
basal tissue on which epithelium can grow. In addition, they provide vessels and a blood supply 1172 
to diseased cornea. These vessels aid in healing of resistant infections and provide serum-based 1173 
growth factors. Vascularized structures are also very resistant to ulceration and perforation 1174 
(Conn et al., 1980). The original flap procedure involved performing a 360º peritomy, debriding 1175 
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the corneal epithelium completely, and mobilizing the superior conjunctiva to cover the entire 1176 
cornea. Various modifications have been made to that original technique in an attempt to 1177 
decrease complications and increase the success rate, especially the use of partial pedicle grafts 1178 
(Alino et al., 1998; Khodadoust and Quinter, 2003; Sandinha et al., 2006).  It is generally 1179 
accepted that conjunctival flaps need to retain a pedicle to ensure continued supply of blood. 1180 
This makes mobilization and advancement of conjunctiva on to the cornea difficult in cases 1181 
where the underlying pathology for NK, such as chemical burns, affects the conjunctiva also. 1182 
Dua et al. proposed use of a free autologous conjunctival graft from the opposite eye or from a 1183 
distal surviving site in the same eye (Dua et al., 2012). The free graft covers the affected cornea 1184 
in whole or part; the peripheral margin of the graft or at least part of it and the edge(s) sutured to 1185 
viable tissue (with a blood supply intact). This allows blood vessels to connect with the vessels 1186 
and in the graft that carry blood to the affected cornea, helping it heal. Other methods that have 1187 
been tried for grafts to maintain globe integrity include buccal mucous membrane grafts, split 1188 
thickness dermal grafts, and tenon’s capsule grafts (Ma'luf and Awwad, 2005; Mauriello et al., 1189 
1988; Reim et al., 1992). 1190 
10.3.7 Corneal transplants 1191 
When all other options have failed to heal progressive corneal ulceration, a tectonic 1192 
corneal transplant is often the last resort.  Corneal transplants are preferably done as a planned 1193 
procedure after the active ulceration has resolved and all inflammation has settled, though often 1194 
it has to be performed in cases with impending perforation of perforated corneas. Risk of 1195 
rejection and failure is greater with ‘hot grafts’ and grafts performed in background of NK are at 1196 
high risk of failure (Jonas et al., 2001). However, tectonic grafts that are performed to preserve 1197 
the structural integrity of the cornea have some advantages over other treatment modalities. The 1198 
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vision is often better than that achieved with glue, amniotic membranes, or conjunctival flaps if 1199 
the visual axis is involved (Killingsworth et al., 1993; Vanathi et al., 2002). Corneal grafts may 1200 
be lamellar or penetrating. The advantage of lamellar transplant is that the anterior chamber is 1201 
not entered in corneas that have not perforated. However, they are often technically challenging 1202 
and may have poor visual outcomes (Soong et al., 2000). Jonas et al. compared the outcomes of 1203 
penetrating keratoplasty in patients with corneal ulcers and patients with corneal scars from 1204 
healed corneal ulcers (Jonas et al., 2001). They found that the visual outcomes were poorer and 1205 
there were more episodes of rejection and loose sutures in the tectonic grafts. However, the 1206 
visual outcomes were much better than with the lamellar transplants. Elective corneal 1207 
transplantation for visual rehabilitation in patients with NK carries a high risk of failure. These 1208 
patients have poor epithelial wound healing and are prone to inflammation. Both of these factors 1209 
significantly increase the risk of melting, perforation and rejection. 1210 
A conjunctival flap is recommended when descemetocele or perforation recurs despite 1211 
previous corneal transplantation (Vasseneix et al., 2006). The Boston keratoprosthesis 1212 
implantation has emerged as an effective modality for visual rehabilitation in such patients 1213 
(Katzman and Jeng, 2014; Pavan-Langston and Dohlman, 2008). 1214 
10.3.8 Direct neurotisation 1215 
Direct neurotization of the cornea using the contralateral supraorbital and supratrochlear 1216 
branches of the ophthalmic division of the trigeminal nerve has been performed for restoring the 1217 
corneal sensitivity in patients with unilateral facial palsy and anesthetic cornea. Terzis et al 1218 
(Terzis et al., 2009) described a novel surgical procedure in which donor nerve branches are 1219 
inserted at the contralateral anesthetic corneal limbus for sensory neurotization. Use of the sural 1220 
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nerve for this purpose has also been described (Bains et al., 2015; Elbaz et al., 2014). This 1221 
surgical technique, although difficult to perform, preserves ocular anatomy and cosmesis and 1222 
restores function. A step-ladder approach to the use of medical, non-surgical and surgical 1223 
interventions in the management of NK is given in table 3. 1224 
 1225 
11. Future Directions 1226 
Testing corneal sensitivity is key to recognition and diagnosis of NK. Corneal sensitivity 1227 
testing is not routinely undertaken in clinical practice and is inadequately performed with the 1228 
help of a cotton whisp or tissue paper rolled to a fine tapering end with bare fingers (unsterile). 1229 
This, at best gives a qualitative estimate of the central cornea as it is usually performed in the 1230 
central cornea ignoring the four quadrants. The Cochet Bonnet aesthesiometer gives a reasonable 1231 
quantitative estimate of corneal sensitivity. Its nylon thread is re-usable, usually cleaned with a 1232 
sugical wipe but is not sterile.  The Belmonte aesthesiometer is a non-contact device,  more 1233 
sophisticated and accurate but unwieldy andfor practical reasons is not widely used. As a result, 1234 
NK remains an under-diagnosed condition. There is a strong need for a method or device that is 1235 
clinically practical and easy to use in busy clinics, yet providing a quantitative (or semi 1236 
quantitative) assesment. Research is underway to produce a standardised clinical tool that is 1237 
sterile, disposable, easy to use and give semi-quantitative assessment of corneal sensitivity. Such 1238 
a device would be very desirable and should be available for trial in the next year or two. 1239 
Corneal hyperaesthesia is recognised as a feature of corneal pathology and may also be part 1240 
of the process that evetually culminates in hypoaesthesia and complete loss of sensation.This can 1241 
be associated with increased firing of existing nerves or abberant regeneration of nerves. There is 1242 
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no method available to test increased sensitivity. In future, as understanding of hyperaesthesia 1243 
and methods of assessing it will become important.   1244 
The pathophysiology of NK is ill-understood and often compounded by the pathophysiology 1245 
of the causative underlying condition or agent.  This makes for inadequate staging or grading of 1246 
the condition and treatment strategies are difficult to target towards specific factors in the 1247 
etiopathogenesis. In addition, interactions between disease processes and iatrogenic interventions 1248 
make diagnosis and treatments even more difficult; therapeutic protocols lack standardization 1249 
and duration of treatment remains unclear as reccurences may occur if treatment is tapered too 1250 
early or in cases where the underlying condition cannot be cured.  Lack of functional innervation 1251 
and consequent deprivation of trophic environment increases risk of delayed or poor post 1252 
surgical wound healing, limiting surgical options for restoration of vision, in coneas affected by 1253 
NK. Nevertheless, an Nevertheless, affection of the sensory nerves of the cornea is common to 1254 
all stages/grades of NK. Until recently and there wais no drug that addresseds this factor. The 1255 
recent advent of NGF with proven clinical efficacy through clinical trials offers a lot of promise. 1256 
and oOther topically administered products that promote nerve health and growthepithelial 1257 
healing,  are in the pipeline. as therapeutic agents specifically aiming to restore effects of nerve 1258 
damage, offer promise. These products should become available for  clinical use in the near 1259 
future leading to post marketing clinical trials, which in turn will establish the true potential of 1260 
the products. 1261 
Surgical neurotisation of the cornea with nerve grafts is an elaborate procedure, still in its 1262 
infancy but with exciting and promising possibilities. The foreseeable future will see 1263 
improvement in surgical techniques and improved outcomes making the surgery available to 1264 
more patients by a greater number of trained surgeons. High resolution in vivo confocal 1265 
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microscopy imaging of the cornea following neurotisation or treatment with rhNGF or Netrin-1266 
1should allow direct visualisation of the new nerves sprouting from the transplanted trunks. 1267 
Patients with NK manifest local (eye specific) symptoms, general health and social and 1268 
psychological problems. Due to duration of the disease, its potential visual impact and the burden 1269 
of the range of treatment options, quality of life can be severely affected by NK. There is a lack 1270 
of a specific NK related tool to accurately assess quality of life (QoL) in these individuals. The 1271 
main objectives of future therapies will thus be to tackle all these complex issues to heal the 1272 
cornea, to prevent or reverse vision impairment and improve quality of life of NK patients.  1273 
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 1975 
15. Legends for Figures 1976 
 1977 
Fig. 1. Diagram illustrating the afferent sensory pathway from the cornea and conjunctiva to the 1978 
trigeminal ganglion and the efferent sympathetic and parasympathetic nerve pathways. Adapted 1979 
and modified from Stern 2013. 1980 
 1981 
Fig. 2. Effect of benzalkonium chloride (BAK) on cultured corneal epithelial cells. H0 (hour 1982 
zero) the vertical gap created by the ‘scratch’ in a confluent layer of corneal epithelial cells is 1983 
visible. H8 (hour 8) the gap is fully closed to establish a confluent sheet again compared to the 1984 
BAK group where the defect persists. 1985 
 1986 
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Fig. 23. Sequence of events leading to epithelial disturbance, epithelial loss and stromal lysis as 1987 
neurotrophic keratopathy progresses through different stages/grades of severity.  1988 
 1989 
Fig. 34. Grades/stages of neurotrophic keratopathy (NK). (a) Slit lamp broad beam illumination 1990 
showing central, confluent punctate lesions giving the central cornea a dull lack-lustre 1991 
appearance following photorefractive keratectomy (ocular surface syndrome) (OSN). (b) The 1992 
same cornea stained with fluorescein showing that most of the lesions take up stain highlighting 1993 
the epitheliopathy. (c) OSN following laser in-situ keratomileusis. Fluorescein stain of the cornea 1994 
shows coarse, centrally located, almost confluent ‘keratitis’. (a – c represent grade/stage 1 NK). 1995 
(d) The central cornea shows a diffuse haze with a large epithelial defect. (e) The central cornea 1996 
is hazy with an epithelial defect with superficial and deep stromal vessels. (f) There is a large 1997 
corneal epithelial defect with a relatively clear stroma. Images d-f represent grade/stage 2 NK. 1998 
The white, rolled margins of the defects is a typical sign of a non-healing epithelial defect. (g) 1999 
Slit view showing stromal melting to mid depth in a case of herpes zoster keratitis. (h) Deep 2000 
stromal ulceration in a child with congenital anaesthetic cornea. (i) A large corneal ulcer in a 2001 
case of treated acanthamoeba keratitis. Inset illustrated the stromal roughening, over which the 2002 
epithelium did not migrate. Note the absence of corneal vascularization. Images g to i represent 2003 
grade/stage 3 NK. 2004 
 2005 
Fig. 54. Complications of neurotrophic keratopathy (NK). (a) Three months following a 2006 
chemical burn the eye shows limbal ischaemia in the inferior half with a large hypopyon. (b) The 2007 
same eye as in (a) stained with fluorescein. A large non healing epithelial defect is seen. Corneal 2008 
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sensation was absent in the lower half. (c) NK with superadded bacterial infection, stromal 2009 
melting and ectasia. (d) Same eye as in (c) showing that the area of epithelial defect, stained with 2010 
fluorescein, corresponds to the stromal involvement. (e) NK in a penetrating corneal graft in an 2011 
aphakic eye, showing a ‘silent’ central perforation with prolapse of the vitreous. (f) NK with 2012 
Descemetocele and perforation showing aqueous leakage (Sidel positive). The corneas in (e) and 2013 
(f) developed perforation in the absence of infection. 2014 
 2015 
Fig. 56. Right eye of a patient with mild/stage 1 neurotrophic keratopathy (NK). (a) The lower 2016 
half of the cornea shows multiple, almost confluent, punctate erosions stained with fluorescein. 2017 
The upper half has a normal tear film. Inset shows the white appearance of the epitheliopathy. 2018 
Cochet-Bonnet aesthesiometery measured 60mm in the upper half and 15mm in the lower half. 2019 
(b) Higher magnification broad beam slit lamp illumination shows the white lesion on the right 2020 
hand side of the beam and ‘vesicular’ appearance or intra-epithelial microcysts on the left side of 2021 
the beam. Intraepithelial vesicular lesions are part of the epitheliopathy of NK. Superficial 2022 
lesions rupture and stain with fluorescein.   2023 
Fig. 67. Left eye of the same patient as in figure 5. (a) The patient underwent penetrating 2024 
keratoplasty for herpes simplex virus keratitis related scars. Post-operatively she presented with 2025 
moderate/grade 2 neurotrophic keratopathy (NK). An epithelial defect with underlying and 2026 
surrounding stromal haze is seen. (b) On fluorescein staining the ulcer is delineated. The 2027 
surrounding epithelium shows coarse punctate keratitis. (c) NK progressed to severe grade/ stage 2028 
3. Various treatment options were tried including an amniotic membrane patch. The ulcer healed 2029 
but left a scarred vascularized cornea, shown a year later. (d) Two years post-graft the corneal 2030 
graft has failed with a dense scar and further vascularization. Corneal sensations were absent. 2031 
84 
 
The case illustrates that with conventional therapeutic interventions, ‘successful’ healing of 2032 
severe NK can be associated with severely compromised vision. 2033 
 2034 
Fig. 78.  Progression of neurotropic keratopathy (NK). (a) Following successful treatment of 2035 
acanthamoeba keratitis, there was marked reduction of corneal sensation (Cochet-Bonnet 5 mm) 2036 
with moderate/stage 2 NK. (b) NK progressed with stromal lysis and (c) perforation, despite 2037 
treatment.  2038 
 2039 
Fig. 89. Diagnostic algorithm for neurotrophic keratopathy. 2040 
 2041 
Fig. 910. Testing corneal sensation. (a) Testing corneal sensation with a wisp of cotton. This is a 2042 
qualitative test and easy to perform at he bedside. However, the cotton is usually not sterile or 2043 
even if so, is drawn into a this wisp with ‘un-sterile’ fingers. (b) testing corneal sensation with 2044 
the Cochet-Bonnet aesthesiometer. The fine nylon thread is sterilised by wiping it with an 2045 
alcohol swab. (c) The set up of the Belmonte aesthesiometer. A controlled jet of air is targeted on 2046 
the cornea and the patient’s response is both observed and interrogated. 2047 
 2048 
Fig. 1011. (a) A case of severe neurotrophic keratopathy (NK) examined by in-vivo confocal 2049 
microscopy (IVCM). (b) IVCM of the ulcerated area appears as a dark hypo-reflective patch 2050 
with scattered fine hyper-reflective speck (possible inflammatory cells/reactive keratocytes) and 2051 
surrounded by the hyper-reflective epithelial cells of the ulcer margin. (c) A large stromal nerve 2052 
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is seen as a hyper-reflective line in the deep stroma of the peripheral non-ulcerated area. (d) The 2053 
stroma in the vicinity of the ulcer shows disorganization with reactive keratocytes. (e) The 2054 
epithelium in the vicinity of the ulcer shows altered morphology and absence of the sub-basal 2055 
plexus. 2056 
 2057 
Fig. 1112. Anterior segment optical coherence tomography (ASOCT) in neurotrophic kertopathy 2058 
(NK). (a) Severe NK with stromal melting. (b) ASOCT of the cornea illustrating the depth of the 2059 
ulcer and its contour. The facet is filled with instilled tear drops. The density of the stroma 2060 
(yellow red colour) is greater in the stroma around the ulcer. Anterior bowing of the posterior 2061 
corneal layer can be appreciated indicating the start of a Descemetocele. 2062 
 2063 
Fig. 1213. Response to treatment with recombinant nerve growth factor (NGF) eye drops. (a) 2064 
Moderate grade/stage 2 neurotrophic keratopathy. (b) & (c) complete closure of the epithelial 2065 
defect occurred with NGF drops instilled six times a day for a few weeks.  2066 
Fig. 1314. Beneficial effect of botulinum toxin induced ptosis in neurotrophic keratopathy (NK). 2067 
(a) The cornea shows a large area of moderate grade/stage 2 NK. (b) Complete ptosis of the 2068 
upper lid is achieved with botulinum toxin injection. (c) Healing of NK at 2 weeks and (d) 2069 
complete healing at 4 weeks. 2070 
 2071 
Fig. 1415. Tarsorrhapy, arguably the most effective surgical intervention in neurotrophic 2072 
keratopathy (NK). (a) A cornea with unilateral chemical burn was treated with autologous limbal 2073 
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transplant. A persistent epithelial defect is seen (NK moderate grade/stage 2). (b) A lateral 2074 
tarsorrhaphy was performed. (c) Complete healing of NK is seen. (d), (e) and (f) are 2075 
corresponding fluorescein stained images showing the original epithelial defect, reduction in size 2076 
of the defect and complete healing respectively. 2077 
 2078 
Fig. 1516. Amniotic membrane transplant (AMT) in management of severe neurotrophic 2079 
keratopathy (NK). (a) Severe (stage 3) NK following trabeculectomy operation, which did not 2080 
respond to medical management. The central stroma is necrotic and surrounded by a gutter of 2081 
stromal lysis. (b) The ‘gutter’ is epithelialized but no epithelium has grown over the central 2082 
necrotic stroma (fluorescein stained). (c) An AMT (Omnigen 500 graft) with a running 10 ‘O 2083 
nylon suture was used to cover the defect after dissecting off the necrotic stroma.  2084 
 2085 
Fig. 1617. Corneal perforation managed by application of cyanoacrylate tissue adhesive. (a) A 2086 
case of bacterial corneal ulcer, medically treated with intensive antibiotics. The ulcer was 2087 
rendered sterile but remained as a persistent defect with reduced sensation, progressing to 2088 
perforation at two sites.  Multiple patches of cyanoacrylate glue were required to seal the 2089 
perforations. (c) Two months later, the glue has been dislodged revealing a scarred and 2090 
vascularized cornea. The perforations have sealed and the anterior chamber is formed.  2091 
 2092 
 2093 
Table 1. Terms used to describe corneal nerves related pathology. 
 
Non-Healing corneal epithelial defects 
 
87 
 
Persistent corneal epithelial defects 
 
Slow-healing corneal epithelial defects 
 
Neuropathic keratitis (epithelial defects) 
 
Neurotrophic keratitis/keratopathy 
 
Neuroparalytic keratitis/keratopathy 
 
Ocular surface syndrome and Neurotrophic 
epitheliopathy post-Lasik 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Common causes of ocular surface nerve damage that may lead to neurotrophic 
keratopathy 
• Genetic   (Morishige et al., 2014)    
o Riley–Day syndrome (familial dysautonomia) 
o Goldenhar–Gorlin syndrome 
o Mobius syndrome 
o Familial corneal hypoaestesia 
 • Systemic 
o Diabetes mellitus. (Lockwood et al., 2006) 
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o Leprosy 
o Vitamin A deficiency 
o Amyloidosis 
o Multiple sclerosis 
 • Central nervous system 
o Neoplasm 
o Aneurysms    
o Stroke 
o Degenerative disorders of the central nervous system (Alzheimers, Parkinsons) 
o Post neurosurgical procedures  
o For acoustic neuroma 
o For trigeminal neuralgia 
o Other surgical injury to the trigeminal nerve 
 • Ocular 
o Post-herpes infections (herpes simplex and herpes zoster) 
o Other infections e.g acanthamoeba with nerve damage related to keratoneuritis 
o Chemical and physical burns 
o Abuse of topical anaesthetics 
o Drug toxicity (timolol, betaxolol, diclofenac sodium, sulphacetamide 30%) 
 o Chronic ocular surface injury or inflammation  
o Ocular surgery 
 Alterations of cornea sensitivity have been observed after cataract surgery even if 
no frank NK has been reported. 
 Laser in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) 
have been have been described as possible causes of NK even if in most cases 
transient. (Wilson and Ambrosio, 2001) 
 Penetrating keratoplasty (PK) and deep anterior lamellar keratoplasty (DALK) 
can cause some degree of corneal denervation. up to 12 months after surgery ,[6] 
but NK is not very frequent in after this  kind of surgery. (Lin et al., 2014)  
 Collagen crosslinking for keratoconus.[8]also show a frequently transient 
reduction of corneal sensitivity (Wasilewski et al., 2013)  
 Development or worsening of NK has been frequently associated with 
vitrectomy for retinal detachment and photocoagulation to treat diabetic 
retinopathy (Banerjee et al., 2014) 
 Postsurgical or laser treatment (trauma of ciliary nerves) Routine, single session, 
indirect laser for proliferative diabetic retinopathy has also been reported as a 
possible cause of NK. (Tinley and Gray, 2009) 
 o Contact lens wear 
o Orbital neoplasia 
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o Corneal dystrophies (lattice, granular) 
 
Adapted from author’s own publication. (Bonini et al., 2003) 
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Table 3: Step-ladder approach to management of NK 
 
Clinical grade 
 
Therapeutic Options Intervention Aim 
 
 
Mild 
(stage 1 ) 
 
 
• Discontinuation of all topical 
medications especially if containing 
preservatives. 
• Evaluation of side effects of systemic 
therapies such as neuroleptic, 
antipsychotic, and antihistamine drugs. 
• Treat concurrent ocular surface 
problems, especially infection of ocular 
surface / lacrimal passage. 
• Anti-inflammatory therapy if 
inflammation present (non-steroidal 
anti-inflammatory drugs can be toxic) 
• Tear substitution / Administration of 
topical preservative-free lubricants. 
• Punctal occlusion. 
• Correction of lid abnormalities. 
• Debridement of sick epithelium. 
 
• Improve epithelial quality 
and transparency. 
• Stabilise epithelium and 
avoid epithelial 
breakdown. 
• Prevent progression to 
Moderate grade (stage 2, 
persistent epithelial 
defect). 
 
Moderate 
(stage 2) 
 
As per Stage 1 and: 
• Prophylactic topical preservative-free 
antibiotics. 
• Prevention of melting with Citrate / 
tetracycline / macrolides (if stromal 
involvement is threatened) 
• Recombinant Human (rh)NGF 
(Cenegermin / Oxervate). 
• Q10 co-enzyme. 
• Cacicol 20 / RGTA. 
• Serum eye drops, platelet-rich plasma  
• Corneal or scleral therapeutic contact 
lenses. 
• Non-surgical Eyelid closure. 
• Debridement of ‘rolled’ edges of 
epithelial defect. 
• Tarsorrhaphy. 
• Amniotic membrane transplantation 
usually single layer as patch. 
• Conjunctival flaps. 
 
 
• Promote epithelial healing  
• Prevent the 
occurrence/recurrence of 
the epithelial breakdown 
• Prevent progression to 
Severe grade (stage 3, 
stromal lysis) 
 
 As per Stage 2 and:  
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Severe 
(stage 3) 
 
• rhNGF and RGTA are likely to be of 
particular help. 
• Amniotic membrane, multilayer, 
usually as graft. Can be combined with 
tarsorrhaphy. 
• Corneal grafts (tectonic, lamellar or 
full thickness). 
 
In the event of perforation 
• Cyanoacrylate tissue adhesive with 
therapeutic contact lens. 
• Fibrin glue. 
• Amniotic membrane graft or corneal 
grafts. 
 
• Promote corneal healing. 
• Prevent further corneal 
stromal lysis and 
perforation. 
  
 
 
  
For each grade, all interventions listed may not be required. 
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Table 4: Summary of ocular lubricants 
Viscosity Compound 
Low Hypromellose 0.3% 
Polyvinyl alcohol 
Thin-medium Carbomers 
Carmellose 0.5-1.0% 
Thick - medium Hyaluronates (0.1-0.4%) 
Trehalose 3% 
High Paraffin/white petroleum 
Retinoic acid ointment 
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Table 5. Shows efficacy of cenegermin 20 µg/ml compared to vehicle in the two studies. 
 
 
 
 Study NGF0212 Study NGF 0214 
Results after 4 and 8 weeks of treatment Week 4 Week 8 Week 4 Week 8 
Complete corneal healing rate 
OXERVATE 58.0 % 74.0 % 56.5 % 69.6 % 
vehicle 19.6 % 43.1 % 37.5 % 29.2 % 
(p value) (0.001) (0.002) (0.191) (0.006) 
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